Materiały źródłowe

• #1 Hereditary Hemorrhagic Telangiectasia (HHT)

  https://my.clevelandclinic.org/health/diseases/15618-hereditary-hemorrhagic-telangiectasia-hht

  How is hereditary hemorrhagic telangiectasia (HHT) treated? There is no cure for HHT, but treatments can improve symptoms and reduce the risk of serious complications. Scientists are still studying ways to treat HHT and advances are made in medicines that specifically target the formation of blood vessels. […] Treatment may include: Ablation, a minor surgery to zap an area with a laser to make it stop bleeding. […] Embolization, a minor surgery to block an area that is bleeding or has potential risk for bleeding. […] Iron replacement or blood transfusion to treat anemia. […] Lubrication and moisture for nosebleeds. […] Radiation or surgery to remove AVMs. […] Anti-angiogenic medical therapies with infusions and pills. […] You may need to see a specialist for treatment related to specific body systems, such as your liver, lungs, gastrointestinal system and brain.

• #2 Hereditary haemorrhagic telangiectasia (HHT)

  https://www.nhs.uk/conditions/hereditary-haemorrahagic-telangiectasia/

  There’s no cure for HHT, but there are effective treatments. […] Some people can be treated by a GP and others need to be under the care of a specialist. […] If you have regular nosebleeds you will probably lose a lot of iron through this loss of blood, especially if you also bleed from telangiectasia in the gut. It may be necessary to replace the lost iron with iron supplements. Dietary changes alone may not be enough. […] People with severe nosebleeds may need emergency nasal packing, where the nose is packed with ribbon gauze or a special nasal sponge. […] Some people may need to see an ear, nose and throat specialist for treatment. Laser therapy may help. […] More severe cases may be treated with skin grafting or other surgery. […] If a lot of blood has been lost from bleeding inside the body or after nosebleeds, a blood transfusion may be needed.

• #3 Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist’s perspective

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6119150/

  Hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome, is an autosomal dominant disorder that causes abnormal blood vessel formation. […] Optimal treatment is best delivered via a multidisciplinary approach with appropriate diagnosis, screening and local and/or systemic management of lesions. Anti-angiogenic agents such as bevacizumab have emerged as a promising systemic therapy in reducing bleeding complications but are not curative. […] Bevacizumab, a recombinant humanized monoclonal antibody that blocks angiogenesis via VEGF inhibition, appears to be promising in HHT as an intravenous formulation for reducing the frequency and severity of epistaxis and impacting quality of life. […] Treatment options are patient-specific and are best grouped by local versus systemic measures in a stepwise approach. There are no standard medical therapies for HHT given the few randomized trials in this field. Management can include supportive care, lesion-specific therapy, and systemic treatment.

• #4 Hereditary hemorrhagic telangiectasia – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/hht/diagnosis-treatment/drc-20351136

  If you or your child has HHT, if you can, seek treatment at an HHT Center of Excellence. HHT is a rare condition that is best managed at centers that treat all aspects of this condition at every age. So it can be hard to find a specialist to treat it. […] In the United States, Cure HHT names HHT Centers of Excellence for being able to diagnose and treat all aspects of the condition. Mayo Clinic is an HHT Center of Excellence and cares for many people and their family members diagnosed with HHT. […] Medicines that help stop the bleeding linked with HHT can be divided into three broad groups: […] One treatment for HHT is bevacizumab (Avastin). Avastin goes through a tube in a vein, called intravenous. Other medicines healthcare professionals use to block blood vessel growth include pazopanib (Votrient), pomalidomide (Pomalyst) and tacrolimus (Prograf, Protopic, others).

• #5 Hereditary Hemorrhagic Telangiectasia (HHT) Treatment | ColumbiaDoctors

  https://www.columbiadoctors.org/specialties/lung-breathing-disorders/our-services/hereditary-hemorrhagic-telangiectasia-hht/diagnosis-and-treatment-columbia

  With an entire team of dedicated specialists to coordinate care, the Cure HHT designated Centers of Excellence are the best places to access expert HHT care. Columbia University Irving Medical Center/NewYork-Presbyterian is the only Cure HHT Center of Excellence in New York state. […] Your treatment will depend on the severity of your symptoms and which organ systems are involved. You may be referred for treatment to one or more specialists in interventional radiology, ENT, dermatology, pulmonology, pediatrics, neurosurgery, or interventional neuroradiology. Our doctors work closely together to ensure that every patient receives the best possible care. […] Treatment for nosebleeds depends on their frequency and severity. Treatment can range from home remedies, such as humidifiers and over-the-counter ointments, to surgery. Treatments include:

• #6 Hereditary hemorrhagic telangiectasia – Wikipedia

  https://en.wikipedia.org/wiki/Hereditary_hemorrhagic_telangiectasia

  Hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu disease and Osler-Weber-Rendu syndrome, is a rare autosomal dominant genetic disorder that leads to abnormal blood vessel formation in the skin, mucous membranes, and often in organs such as the lungs, liver, and brain. […] Treatment focuses on reducing bleeding from telangiectasias, and sometimes surgery or other targeted interventions to remove arteriovenous malformations in organs. Chronic bleeding often requires iron supplements, iron infusions and sometimes blood transfusions. […] Treatment of HHT is symptomatic (it deals with the symptoms rather than the disease itself), as there is no therapy that stops the development of telangiectasias and AVMs directly. Furthermore, some treatments are applied to prevent the development of common complications.

• #7 Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist’s perspective

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6119150/

  Hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome, is an autosomal dominant disorder that causes abnormal blood vessel formation. […] Optimal treatment is best delivered via a multidisciplinary approach with appropriate diagnosis, screening and local and/or systemic management of lesions. Anti-angiogenic agents such as bevacizumab have emerged as a promising systemic therapy in reducing bleeding complications but are not curative. […] Bevacizumab, a recombinant humanized monoclonal antibody that blocks angiogenesis via VEGF inhibition, appears to be promising in HHT as an intravenous formulation for reducing the frequency and severity of epistaxis and impacting quality of life. […] Treatment options are patient-specific and are best grouped by local versus systemic measures in a stepwise approach. There are no standard medical therapies for HHT given the few randomized trials in this field. Management can include supportive care, lesion-specific therapy, and systemic treatment.

• #8

  https://haematologica.org/article/view/8582

  Hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome, is an autosomal dominant disorder that causes abnormal blood vessel formation. Optimal treatment is best delivered via a multidisciplinary approach with appropriate diagnosis, screening and local and/or systemic management of lesions. Anti-angiogenic agents such as bevacizumab have emerged as a promising systemic therapy in reducing bleeding complications but are not curative. Other pharmacological agents include iron supplementation, antifibrinolytics and hormonal treatment. […] Treatment options are patient-specific and are best grouped by local versus systemic measures in a stepwise approach. There are no standard medical therapies for HHT given the few randomized trials in this field. Management can include supportive care, lesion-specific therapy, and systemic treatment.

• #9 Hereditary Hemorrhagic Telangiectasia (HHT) Treatment | ColumbiaDoctors

  https://www.columbiadoctors.org/specialties/lung-breathing-disorders/our-services/hereditary-hemorrhagic-telangiectasia-hht/diagnosis-and-treatment-columbia

  With an entire team of dedicated specialists to coordinate care, the Cure HHT designated Centers of Excellence are the best places to access expert HHT care. Columbia University Irving Medical Center/NewYork-Presbyterian is the only Cure HHT Center of Excellence in New York state. […] Your treatment will depend on the severity of your symptoms and which organ systems are involved. You may be referred for treatment to one or more specialists in interventional radiology, ENT, dermatology, pulmonology, pediatrics, neurosurgery, or interventional neuroradiology. Our doctors work closely together to ensure that every patient receives the best possible care. […] Treatment for nosebleeds depends on their frequency and severity. Treatment can range from home remedies, such as humidifiers and over-the-counter ointments, to surgery. Treatments include:

• #10 Diagnosis and Treatment of Hereditary Hemorrhagic Telangiectasia

  https://pmc.ncbi.nlm.nih.gov/articles/PMC5472075/

  Hereditary hemorrhagic telangiectasia (HHT) is a rare genetic disorder known for its debilitating symptoms. More than 90% of patients with HHT experience epistaxis, and they average up to 18 bleeds per month. […] During active epistaxis, the effective emergency techniques of locally applied pressure, nasal packing anteriorly and/or posteriorly, and cauterization are effective. Medical treatment with antiestrogen therapy has shown promising results, but further research is needed to determine the long-term side effects and the limitations of lifelong therapy. […] Interventional treatments in life-threatening and/or severe circumstances will continue to be used because of their effectiveness. Research into the pathophysiology of HHT has led to the development of potential therapies that prevent and decrease the severity of epistaxis, but the current evidence is insufficient to ascertain best practice. At present, appropriate management of acute epistaxis coupled with early diagnosis and referral to an ear, nose, and throat specialist should be the mainstay of treatment.

• #11 Hereditary hemorrhagic telangiectasia – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/hht/diagnosis-treatment/drc-20351136

  Serious nosebleeds are one of the most common signs of HHT. These sometimes happen daily. They can cause so much blood loss that you become anemic. You might need to receive blood, called a transfusion, and iron through an arm vein. […] Procedures to lower the number of nosebleeds and lessen how bad they are may include: […] In this procedure, a healthcare professional threads a long, slender tube through the blood vessels to the AVM. Then the health professional puts in a plug or a metal coil to block blood from entering the AVM. This shrinks and heals the AVM over time. Embolization treats lung and brain AVMs, but not liver AVMs. […] Rarely, treatment for AVMs in the liver is a liver transplant.

• #12 Hereditary Hemorrhagic Telangiectasia (HHT) Treatment | ColumbiaDoctors

  https://www.columbiadoctors.org/specialties/lung-breathing-disorders/our-services/hereditary-hemorrhagic-telangiectasia-hht/diagnosis-and-treatment-columbia

  With an entire team of dedicated specialists to coordinate care, the Cure HHT designated Centers of Excellence are the best places to access expert HHT care. Columbia University Irving Medical Center/NewYork-Presbyterian is the only Cure HHT Center of Excellence in New York state. […] Your treatment will depend on the severity of your symptoms and which organ systems are involved. You may be referred for treatment to one or more specialists in interventional radiology, ENT, dermatology, pulmonology, pediatrics, neurosurgery, or interventional neuroradiology. Our doctors work closely together to ensure that every patient receives the best possible care. […] Treatment for nosebleeds depends on their frequency and severity. Treatment can range from home remedies, such as humidifiers and over-the-counter ointments, to surgery. Treatments include:

• #13 Osler-Weber-Rendu Disease (Hereditary Hemorrhagic Telangiectasia) Treatment & Management: Approach Considerations, Treatment of Epistaxis, Treatment of Gastrointestinal Bleeding

  https://emedicine.medscape.com/article/2048472-treatment

  Epistaxis is often recurrent, necessitating multiple treatments. Moderate and mild epistaxis can be treated medically or with endoscopic ablation; severe epistaxis calls for surgical treatment. […] Nonoperative treatment of epistaxis may include the following: Iron supplementation, Humidification, Packing, Transfusion, Estrogen therapy, Aminocaproic acid, Electrocautery and argon beam ablation, Neodymium:yttrium-aluminum-garnet (Nd:YAG) laser ablation. […] In more severe cases, iron replacement may be indicated because of blood loss. Humidification of the ambient air helps decrease the amount of mucosal bleeding. Hormone therapy, including antiestrogen therapy with tamoxifen, for the treatment of epistaxis due to HHT has produced good responses, though its use remains controversial. […] Antifibrinolytics (eg, aminocaproic acid) may be used to enhance hemostasis when fibrinolysis contributes to bleeding.

• #14 HHT | Symptoms, Diagnosis & Treatment

  https://www.cincinnatichildrens.org/health/h/hht

  – Embolization: In this technique, a doctor inserts a catheter into an artery in your groin. It is then threaded through your arteries into the feeding artery of the AVM. A substance (ex: coil) is then inserted to block blood flow into the AVM. […] – Lobectomy: In this technique, the part of the lung that has the AVM is removed. […] Treatment of Nosebleeds […] – Use of a humidifier […] – Use of a water-based nasal lubricant […] – Possible uses of oral or topical medicines are being investigated […] – Coagulation therapy (laser coagulation, cautery) […] – Surgery (septal dermoplasty, Youngs procedure) […] Treatment of Anemia […] – Oral iron […] – IV iron replacement […] – Red blood cell transfusions […] – IV bevacizumab / avastin

• #15 Hereditary haemorrhagic telangiectasia (HHT)

  https://www.nhs.uk/conditions/hereditary-haemorrahagic-telangiectasia/

  There’s no cure for HHT, but there are effective treatments. […] Some people can be treated by a GP and others need to be under the care of a specialist. […] If you have regular nosebleeds you will probably lose a lot of iron through this loss of blood, especially if you also bleed from telangiectasia in the gut. It may be necessary to replace the lost iron with iron supplements. Dietary changes alone may not be enough. […] People with severe nosebleeds may need emergency nasal packing, where the nose is packed with ribbon gauze or a special nasal sponge. […] Some people may need to see an ear, nose and throat specialist for treatment. Laser therapy may help. […] More severe cases may be treated with skin grafting or other surgery. […] If a lot of blood has been lost from bleeding inside the body or after nosebleeds, a blood transfusion may be needed.

• #16 Osler-Weber-Rendu Disease (Hereditary Hemorrhagic Telangiectasia) Treatment & Management: Approach Considerations, Treatment of Epistaxis, Treatment of Gastrointestinal Bleeding

  https://emedicine.medscape.com/article/2048472-treatment

  Epistaxis is often recurrent, necessitating multiple treatments. Moderate and mild epistaxis can be treated medically or with endoscopic ablation; severe epistaxis calls for surgical treatment. […] Nonoperative treatment of epistaxis may include the following: Iron supplementation, Humidification, Packing, Transfusion, Estrogen therapy, Aminocaproic acid, Electrocautery and argon beam ablation, Neodymium:yttrium-aluminum-garnet (Nd:YAG) laser ablation. […] In more severe cases, iron replacement may be indicated because of blood loss. Humidification of the ambient air helps decrease the amount of mucosal bleeding. Hormone therapy, including antiestrogen therapy with tamoxifen, for the treatment of epistaxis due to HHT has produced good responses, though its use remains controversial. […] Antifibrinolytics (eg, aminocaproic acid) may be used to enhance hemostasis when fibrinolysis contributes to bleeding.

• #17 Hereditary Hemorrhagic Telangiectasia (HHT) | Treatment & Management | Point of Care

  https://www.statpearls.com/point-of-care/141559

  Treatment options are tailored to the patient, and the best approach is based on local versus systemic measures. Due to the few randomized trials, there are no standard therapies for HHT. Management of HHT focuses on supportive care, preventing complications, and reducing symptom severity. […] Epistaxis prevention is the primary goal for HHT-related nosebleeds. Preventative measures include topical moisturizers and emollients, nasal hygiene with humidifiers and saline irrigations, and avoiding triggers and blood thinners. […] Conservative management of ongoing epistaxis includes topical decongestant spray, manual pressure, absorbable nasal packing, and chemical cauterization with silver nitrate. […] Other medical interventions targeting the molecular biology of the disease have been used many of which have gained and lost favor. These medical treatments aim to reduce nosebleeds’ frequency, volume, and severity and improve quality of life. These topical and oral agents include estrogen agents (tamoxifen, raloxifene, and estriol ointment), tranexamic acid, thalidomide, beta-blockers (timolol or propranolol), and vascular endothelial growth factor (VEGF) inhibitors (bevacizumab).

• #18 Hereditary haemorrhagic telangiectasia (HHT)

  https://www.nhs.uk/conditions/hereditary-haemorrahagic-telangiectasia/

  There’s no cure for HHT, but there are effective treatments. […] Some people can be treated by a GP and others need to be under the care of a specialist. […] If you have regular nosebleeds you will probably lose a lot of iron through this loss of blood, especially if you also bleed from telangiectasia in the gut. It may be necessary to replace the lost iron with iron supplements. Dietary changes alone may not be enough. […] People with severe nosebleeds may need emergency nasal packing, where the nose is packed with ribbon gauze or a special nasal sponge. […] Some people may need to see an ear, nose and throat specialist for treatment. Laser therapy may help. […] More severe cases may be treated with skin grafting or other surgery. […] If a lot of blood has been lost from bleeding inside the body or after nosebleeds, a blood transfusion may be needed.

• #19 Osler-Weber-Rendu Disease (Hereditary Hemorrhagic Telangiectasia) Treatment & Management: Approach Considerations, Treatment of Epistaxis, Treatment of Gastrointestinal Bleeding

  https://emedicine.medscape.com/article/2048472-treatment

  Epistaxis is often recurrent, necessitating multiple treatments. Moderate and mild epistaxis can be treated medically or with endoscopic ablation; severe epistaxis calls for surgical treatment. […] Nonoperative treatment of epistaxis may include the following: Iron supplementation, Humidification, Packing, Transfusion, Estrogen therapy, Aminocaproic acid, Electrocautery and argon beam ablation, Neodymium:yttrium-aluminum-garnet (Nd:YAG) laser ablation. […] In more severe cases, iron replacement may be indicated because of blood loss. Humidification of the ambient air helps decrease the amount of mucosal bleeding. Hormone therapy, including antiestrogen therapy with tamoxifen, for the treatment of epistaxis due to HHT has produced good responses, though its use remains controversial. […] Antifibrinolytics (eg, aminocaproic acid) may be used to enhance hemostasis when fibrinolysis contributes to bleeding.

• #20 Osler-Weber-Rendu Disease (Hereditary Hemorrhagic Telangiectasia) Treatment & Management: Approach Considerations, Treatment of Epistaxis, Treatment of Gastrointestinal Bleeding

  https://emedicine.medscape.com/article/2048472-treatment

  Although estrogen-related hormones and antifibrinolytic agents are commonly used to manage bleeding, some studies suggest that this probably increases the risk of thrombotic events in OWRD patients with pulmonary AVMs. Accordingly, patients should undergo screening for the presence of pulmonary AVMs before treatment is started. […] Pulsed dye laser treatment may be used to photocoagulate telangiectasias in the nasal mucosa. As many as three subsequent treatments may be necessary before any change in bleeding frequency or severity is observed. […] A small prospective randomized trial (26 patients) from Germany of topical estrogen (0.5 mg of 0.1% estriol ointment twice daily) after argon beam coagulation in HHT patients with recurrent epistaxis suggested improved outcome over argon beam coagulation with application of ointment.

• #21 Osler-Weber-Rendu Disease (Hereditary Hemorrhagic Telangiectasia) Treatment & Management: Approach Considerations, Treatment of Epistaxis, Treatment of Gastrointestinal Bleeding

  https://emedicine.medscape.com/article/2048472-treatment

  Epistaxis is often recurrent, necessitating multiple treatments. Moderate and mild epistaxis can be treated medically or with endoscopic ablation; severe epistaxis calls for surgical treatment. […] Nonoperative treatment of epistaxis may include the following: Iron supplementation, Humidification, Packing, Transfusion, Estrogen therapy, Aminocaproic acid, Electrocautery and argon beam ablation, Neodymium:yttrium-aluminum-garnet (Nd:YAG) laser ablation. […] In more severe cases, iron replacement may be indicated because of blood loss. Humidification of the ambient air helps decrease the amount of mucosal bleeding. Hormone therapy, including antiestrogen therapy with tamoxifen, for the treatment of epistaxis due to HHT has produced good responses, though its use remains controversial. […] Antifibrinolytics (eg, aminocaproic acid) may be used to enhance hemostasis when fibrinolysis contributes to bleeding.

• #22 Diagnosis and Treatment of Hereditary Hemorrhagic Telangiectasia

  https://pmc.ncbi.nlm.nih.gov/articles/PMC5472075/

  During active epistaxis episodes, patients with HHT are aided by locally applied pressure, nasal packing anteriorly and/or posteriorly, and cauterization. These techniques are especially effective in anterior bleeds associated with the Kiesselbach plexus, but ongoing severe posterior bleeds may need surgical intervention. […] Research into the molecular biology of the disorder has helped produce management options for preventive approaches to decrease the number of epistaxis episodes as well as their severity. […] Furthermore, promising results have been reported for some medical treatments. Antiestrogen trials have demonstrated good outcomes, with consecutive studies evaluating the benefit of tamoxifen 20 mg/day in patients with HHT. […] Another medical treatment trialed systemically is the commonly used hemostatic agent tranexamic acid. Patients taking tranexamic acid at a dose of 3 g/day had decreased durations of average daily bleeding compared to patients taking placebo.

• #23 Diagnosis and Treatment of Hereditary Hemorrhagic Telangiectasia

  https://pmc.ncbi.nlm.nih.gov/articles/PMC5472075/

  During active epistaxis episodes, patients with HHT are aided by locally applied pressure, nasal packing anteriorly and/or posteriorly, and cauterization. These techniques are especially effective in anterior bleeds associated with the Kiesselbach plexus, but ongoing severe posterior bleeds may need surgical intervention. […] Research into the molecular biology of the disorder has helped produce management options for preventive approaches to decrease the number of epistaxis episodes as well as their severity. […] Furthermore, promising results have been reported for some medical treatments. Antiestrogen trials have demonstrated good outcomes, with consecutive studies evaluating the benefit of tamoxifen 20 mg/day in patients with HHT. […] Another medical treatment trialed systemically is the commonly used hemostatic agent tranexamic acid. Patients taking tranexamic acid at a dose of 3 g/day had decreased durations of average daily bleeding compared to patients taking placebo.

• #24 Osler-Weber-Rendu Disease (Hereditary Hemorrhagic Telangiectasia) Treatment & Management: Approach Considerations, Treatment of Epistaxis, Treatment of Gastrointestinal Bleeding

  https://emedicine.medscape.com/article/2048472-treatment

  Although estrogen-related hormones and antifibrinolytic agents are commonly used to manage bleeding, some studies suggest that this probably increases the risk of thrombotic events in OWRD patients with pulmonary AVMs. Accordingly, patients should undergo screening for the presence of pulmonary AVMs before treatment is started. […] Pulsed dye laser treatment may be used to photocoagulate telangiectasias in the nasal mucosa. As many as three subsequent treatments may be necessary before any change in bleeding frequency or severity is observed. […] A small prospective randomized trial (26 patients) from Germany of topical estrogen (0.5 mg of 0.1% estriol ointment twice daily) after argon beam coagulation in HHT patients with recurrent epistaxis suggested improved outcome over argon beam coagulation with application of ointment.

• #25 Osler-Weber-Rendu Disease (Hereditary Hemorrhagic Telangiectasia) Treatment & Management: Approach Considerations, Treatment of Epistaxis, Treatment of Gastrointestinal Bleeding

  https://emedicine.medscape.com/article/2048472-treatment

  Endovascular embolization for treatment of severe acute epistaxis is another treatment modality that may be considered. […] N-acetylcysteine has been studied as an option for management of recurrent epistaxis in patients with HHT. […] Multiple case reports have illustrated the use of bevacizumab in the treatment of HHT, and the efficacy of this agent for the management of epistaxis in HHT is being studied. […] Nonoperative treatment of GI bleeding may include the following: Estrogen-progesterone therapy, Transfusion, Aminocaproic acid, Endoscopic photoablation or electrocautery, Bevacizumab. […] A treatment regimen involving intranasal administration of diluted bevacizumab has been shown to be clinically effective in patients with HHT1 and severe GI bleeding. […] Life-threatening GI bleeding can often be effectively treated by means of segmental bowel resection.

• #26 Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist’s perspective

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6119150/

  Management of epistaxis with antifibrinolytic agents is another consideration when preventive measures and local or topical treatments fail. […] While the evidence for its use is limited, N-acetylcysteine dosed 600 mg 3 times daily was modestly effective in reducing epistaxis in HHT patients in a pilot study, with the only statistically significant benefit seen in male patients and those with ENG mutations (HHT1). […] The development of anemia can have significant consequences for the patient with HHT. […] Estrogen and progestins (e.g. ethinyl estradiol, norethindrone or mestranol) have been used in HHT patients to reduce bleeding complications. […] Anti-VEGF therapies are relatively new for patients with HHT, and their use has been increasing. […] Bevacizumab, an anti-VEGF antibody, is a rational therapeutic for HHT as it may reduce excessive angiogenesis.

• #27 Hereditary Hemorrhagic Telangiectasia (HHT) | Treatment & Management | Point of Care

  https://www.statpearls.com/point-of-care/141559

  Treatment options are tailored to the patient, and the best approach is based on local versus systemic measures. Due to the few randomized trials, there are no standard therapies for HHT. Management of HHT focuses on supportive care, preventing complications, and reducing symptom severity. […] Epistaxis prevention is the primary goal for HHT-related nosebleeds. Preventative measures include topical moisturizers and emollients, nasal hygiene with humidifiers and saline irrigations, and avoiding triggers and blood thinners. […] Conservative management of ongoing epistaxis includes topical decongestant spray, manual pressure, absorbable nasal packing, and chemical cauterization with silver nitrate. […] Other medical interventions targeting the molecular biology of the disease have been used many of which have gained and lost favor. These medical treatments aim to reduce nosebleeds’ frequency, volume, and severity and improve quality of life. These topical and oral agents include estrogen agents (tamoxifen, raloxifene, and estriol ointment), tranexamic acid, thalidomide, beta-blockers (timolol or propranolol), and vascular endothelial growth factor (VEGF) inhibitors (bevacizumab).

• #28 Osler-Weber-Rendu Disease (Hereditary Hemorrhagic Telangiectasia) Treatment & Management: Approach Considerations, Treatment of Epistaxis, Treatment of Gastrointestinal Bleeding

  https://emedicine.medscape.com/article/2048472-treatment

  Although only a few cases have been reported, the published literature is concordant regarding the potential benefit of thalidomide in reducing the frequency and intensity of epistaxis in HHT patients, improving their hemoglobin levels and therefore reducing the need for transfusions. […] Future research should be directed toward identifying the minimum dose of thalidomide effective in long-term control of bleeding symptoms in HHT patients without inducing thrombotic adverse events. […] It appears to be a potential candidate for the treatment of severe HHT-associated epistaxis unresponsive to conventional therapies. […] Septal dermoplasty can reduce the severity of epistaxis by 75%. This procedure involves replacing the nasal mucosa with autologous skin grafts. Telangiectasias may also develop on the autologous skin grafts, however. Septal dermoplasty decreases the need for, but does not obviate, repeated laser ablation.

• #29 Hereditary Hemorrhagic Telangiectasia (HHT)

  https://my.clevelandclinic.org/health/diseases/15618-hereditary-hemorrhagic-telangiectasia-hht

  How is hereditary hemorrhagic telangiectasia (HHT) treated? There is no cure for HHT, but treatments can improve symptoms and reduce the risk of serious complications. Scientists are still studying ways to treat HHT and advances are made in medicines that specifically target the formation of blood vessels. […] Treatment may include: Ablation, a minor surgery to zap an area with a laser to make it stop bleeding. […] Embolization, a minor surgery to block an area that is bleeding or has potential risk for bleeding. […] Iron replacement or blood transfusion to treat anemia. […] Lubrication and moisture for nosebleeds. […] Radiation or surgery to remove AVMs. […] Anti-angiogenic medical therapies with infusions and pills. […] You may need to see a specialist for treatment related to specific body systems, such as your liver, lungs, gastrointestinal system and brain.

• #30 Osler-Weber-Rendu Disease (Hereditary Hemorrhagic Telangiectasia) Treatment & Management: Approach Considerations, Treatment of Epistaxis, Treatment of Gastrointestinal Bleeding

  https://emedicine.medscape.com/article/2048472-treatment

  Although only a few cases have been reported, the published literature is concordant regarding the potential benefit of thalidomide in reducing the frequency and intensity of epistaxis in HHT patients, improving their hemoglobin levels and therefore reducing the need for transfusions. […] Future research should be directed toward identifying the minimum dose of thalidomide effective in long-term control of bleeding symptoms in HHT patients without inducing thrombotic adverse events. […] It appears to be a potential candidate for the treatment of severe HHT-associated epistaxis unresponsive to conventional therapies. […] Septal dermoplasty can reduce the severity of epistaxis by 75%. This procedure involves replacing the nasal mucosa with autologous skin grafts. Telangiectasias may also develop on the autologous skin grafts, however. Septal dermoplasty decreases the need for, but does not obviate, repeated laser ablation.

• #31 Osler-Weber-Rendu Disease (Hereditary Hemorrhagic Telangiectasia) Treatment & Management: Approach Considerations, Treatment of Epistaxis, Treatment of Gastrointestinal Bleeding

  https://emedicine.medscape.com/article/2048472-treatment

  Although estrogen-related hormones and antifibrinolytic agents are commonly used to manage bleeding, some studies suggest that this probably increases the risk of thrombotic events in OWRD patients with pulmonary AVMs. Accordingly, patients should undergo screening for the presence of pulmonary AVMs before treatment is started. […] Pulsed dye laser treatment may be used to photocoagulate telangiectasias in the nasal mucosa. As many as three subsequent treatments may be necessary before any change in bleeding frequency or severity is observed. […] A small prospective randomized trial (26 patients) from Germany of topical estrogen (0.5 mg of 0.1% estriol ointment twice daily) after argon beam coagulation in HHT patients with recurrent epistaxis suggested improved outcome over argon beam coagulation with application of ointment.

• #32 Hereditary Hemorrhagic Telangiectasia: Diagnosis and Management | AAFP

  https://www.aafp.org/pubs/afp/issues/2010/1001/p785.html

  Hereditary hemorrhagic telangiectasia is an uncommon autosomal dominant disease that occurs in approximately one in 5,000 to 8,000 persons. […] Screening and treatment recommendations have been created in an attempt to limit the morbidity and mortality associated with this disease. Patients with confirmed or suspected hereditary hemorrhagic telangiectasia should be screened for brain and lung arteriovenous malformations using magnetic resonance imaging of the brain and contrast echocardiography. […] Endonasal coagulation should be considered a first-line treatment option for HHT-related epistaxis requiring surgical intervention. […] Laser coagulation of nasal telangiectasias may be helpful for patients who do not respond well to medical treatment and should be considered the first-line treatment option for HHT-related epistaxis requiring surgical intervention.

• #33 Osler-Weber-Rendu Disease (Hereditary Hemorrhagic Telangiectasia) Treatment & Management: Approach Considerations, Treatment of Epistaxis, Treatment of Gastrointestinal Bleeding

  https://emedicine.medscape.com/article/2048472-treatment

  Epistaxis is often recurrent, necessitating multiple treatments. Moderate and mild epistaxis can be treated medically or with endoscopic ablation; severe epistaxis calls for surgical treatment. […] Nonoperative treatment of epistaxis may include the following: Iron supplementation, Humidification, Packing, Transfusion, Estrogen therapy, Aminocaproic acid, Electrocautery and argon beam ablation, Neodymium:yttrium-aluminum-garnet (Nd:YAG) laser ablation. […] In more severe cases, iron replacement may be indicated because of blood loss. Humidification of the ambient air helps decrease the amount of mucosal bleeding. Hormone therapy, including antiestrogen therapy with tamoxifen, for the treatment of epistaxis due to HHT has produced good responses, though its use remains controversial. […] Antifibrinolytics (eg, aminocaproic acid) may be used to enhance hemostasis when fibrinolysis contributes to bleeding.

• #34 Hereditary Hemorrhagic Telangiectasia | HHT Diagnosis, Symptoms

  https://www.vbiny.org/vascular-birthmarks/hereditary-hemorrhagic-telangiectasia/

  Bevacizumab (Avastin) is an inhibitor of blood vessel formation. A combined injection of this medication with intranasal laser treatment has been shown to be beneficial. […] Sclerotherapy may be used alone or in combination with laser treatment. […] The principle behind this technique is to replace abnormal mucosa with skin from another part of the body. […] This surgical procedure closes off the inside of the nose. […] Transcatheter embolization is used to treat AVMs. […] Angiography with embolization is used to treat these lesions. […] Brain MRI is used to rule out the presence of an AVM. If positive, an angiogram will show the architecture of the AVM. […] We have a team of specialists waiting to help you get the specialized treatment you deserve to reduce the appearance and complications of arteriovenous malformations.

• #35 Hereditary hemorrhagic telangiectasia – Wikipedia

  https://en.wikipedia.org/wiki/Hereditary_hemorrhagic_telangiectasia

  Chronic nosebleeds and digestive tract bleeding can both lead to anemia; if the bleeding itself cannot be completely stopped, the anemia requires treatment with iron supplements. Those who cannot tolerate iron tablets or solutions may require administration of intravenous iron, and blood transfusion if the anemia is causing severe symptoms that warrant rapid improvement of the blood count. […] An acute nosebleed may be managed with a variety of measures, such as packing of the nasal cavity with absorbent swabs or gels. […] Frequent nosebleeds can be prevented in part by keeping the nostrils moist, and by applying saline solution, estrogen-containing creams or tranexamic acid; these have few side effects and may have a small degree of benefit. […] Sclerotherapy is another option to manage the bleeding. This process involves injecting a small amount of an aerated irritant (detergent such as sodium tetradecyl sulfate) directly into the telangiectasias.

• #36 Osler-Weber-Rendu Disease (Hereditary Hemorrhagic Telangiectasia) Treatment & Management: Approach Considerations, Treatment of Epistaxis, Treatment of Gastrointestinal Bleeding

  https://emedicine.medscape.com/article/2048472-treatment

  Although only a few cases have been reported, the published literature is concordant regarding the potential benefit of thalidomide in reducing the frequency and intensity of epistaxis in HHT patients, improving their hemoglobin levels and therefore reducing the need for transfusions. […] Future research should be directed toward identifying the minimum dose of thalidomide effective in long-term control of bleeding symptoms in HHT patients without inducing thrombotic adverse events. […] It appears to be a potential candidate for the treatment of severe HHT-associated epistaxis unresponsive to conventional therapies. […] Septal dermoplasty can reduce the severity of epistaxis by 75%. This procedure involves replacing the nasal mucosa with autologous skin grafts. Telangiectasias may also develop on the autologous skin grafts, however. Septal dermoplasty decreases the need for, but does not obviate, repeated laser ablation.

• #37 Osler-Weber-Rendu Disease (Hereditary Hemorrhagic Telangiectasia) Treatment & Management: Approach Considerations, Treatment of Epistaxis, Treatment of Gastrointestinal Bleeding

  https://emedicine.medscape.com/article/2048472-treatment

  Endovascular embolization for treatment of severe acute epistaxis is another treatment modality that may be considered. […] N-acetylcysteine has been studied as an option for management of recurrent epistaxis in patients with HHT. […] Multiple case reports have illustrated the use of bevacizumab in the treatment of HHT, and the efficacy of this agent for the management of epistaxis in HHT is being studied. […] Nonoperative treatment of GI bleeding may include the following: Estrogen-progesterone therapy, Transfusion, Aminocaproic acid, Endoscopic photoablation or electrocautery, Bevacizumab. […] A treatment regimen involving intranasal administration of diluted bevacizumab has been shown to be clinically effective in patients with HHT1 and severe GI bleeding. […] Life-threatening GI bleeding can often be effectively treated by means of segmental bowel resection.

• #38 Information on Hereditary Hemorrhagic Telangiectasia (HHT)

  https://melbentgroup.com.au/hereditary-hemorrhagic-telangiectasia/

  Topical treatment: applying Vaseline or antibiotic creams into the front of the nose can be helpful. […] Tamoxifen is a newer hormonal therapy with reduced side effects and improved symptom control (refer to HHT Tamoxifen patient information sheet). […] Bevacizumab (Avastin) is an antiangiogenic drug that reduces abnormal blood vessel formation. It has been used for severe complications of HHT rather than nosebleeds, but is starting to be looked at as a possible treatment for nosebleeds by injecting or spraying it into the nose, and rarely by administering it into the blood-stream (intravenous). […] Laser treatment: aims to reduce the frequency and severity of nosebleeds by sealing off the individual telangiectasias within the nose. […] Septodermoplasty: telangiectasias are most frequent at the front of the nose, particularly on the nasal septum. […] Closure of the nose (Youngs procedure): this is the only treatment that can stop nosebleeds completely.

• #39 Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist’s perspective

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6119150/

  Hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome, is an autosomal dominant disorder that causes abnormal blood vessel formation. […] Optimal treatment is best delivered via a multidisciplinary approach with appropriate diagnosis, screening and local and/or systemic management of lesions. Anti-angiogenic agents such as bevacizumab have emerged as a promising systemic therapy in reducing bleeding complications but are not curative. […] Bevacizumab, a recombinant humanized monoclonal antibody that blocks angiogenesis via VEGF inhibition, appears to be promising in HHT as an intravenous formulation for reducing the frequency and severity of epistaxis and impacting quality of life. […] Treatment options are patient-specific and are best grouped by local versus systemic measures in a stepwise approach. There are no standard medical therapies for HHT given the few randomized trials in this field. Management can include supportive care, lesion-specific therapy, and systemic treatment.

• #40 Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist’s perspective

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6119150/

  Management of epistaxis with antifibrinolytic agents is another consideration when preventive measures and local or topical treatments fail. […] While the evidence for its use is limited, N-acetylcysteine dosed 600 mg 3 times daily was modestly effective in reducing epistaxis in HHT patients in a pilot study, with the only statistically significant benefit seen in male patients and those with ENG mutations (HHT1). […] The development of anemia can have significant consequences for the patient with HHT. […] Estrogen and progestins (e.g. ethinyl estradiol, norethindrone or mestranol) have been used in HHT patients to reduce bleeding complications. […] Anti-VEGF therapies are relatively new for patients with HHT, and their use has been increasing. […] Bevacizumab, an anti-VEGF antibody, is a rational therapeutic for HHT as it may reduce excessive angiogenesis.

• #41 Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist’s perspective

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6119150/

  Hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome, is an autosomal dominant disorder that causes abnormal blood vessel formation. […] Optimal treatment is best delivered via a multidisciplinary approach with appropriate diagnosis, screening and local and/or systemic management of lesions. Anti-angiogenic agents such as bevacizumab have emerged as a promising systemic therapy in reducing bleeding complications but are not curative. […] Bevacizumab, a recombinant humanized monoclonal antibody that blocks angiogenesis via VEGF inhibition, appears to be promising in HHT as an intravenous formulation for reducing the frequency and severity of epistaxis and impacting quality of life. […] Treatment options are patient-specific and are best grouped by local versus systemic measures in a stepwise approach. There are no standard medical therapies for HHT given the few randomized trials in this field. Management can include supportive care, lesion-specific therapy, and systemic treatment.

• #42

  https://haematologica.org/article/view/9810

  Hereditary hemorrhagic telangiectasia (HHT, Osler-Weber-Rendu disease) is a rare multisystem vascular disorder causing chronic gastrointestinal bleeding, epistaxis, and severe anemia. Bevacizumab, an anti-vascular endothelial growth factor antibody, may be effective to treat bleeding in HHT. This international, multicenter, retrospective study evaluated the use of systemic bevacizumab to treat HHT-associated bleeding and anemia at 12 HHT treatment centers. 238 HHT patients received bevacizumab for a median of 12 (range, 1-96) months. Compared with pretreatment, bevacizumab increased mean hemoglobin by 3.2 g/dL (95% CI, 2.9-3.5 g/dL) and decreased the epistaxis severity score (ESS) by 3.4 (3.2-3.7) points during the first year of treatment. Compared with 6 months pretreatment, RBC units transfused decreased by 82% and iron infusions decreased by 70% during the first 6 months of bevacizumab treatment. Bevacizumab was well tolerated: hypertension, fatigue, and proteinuria were the most common adverse events. In conclusion, systemic bevacizumab was safe and effective to manage chronic bleeding and anemia in HHT.

• #43 Hereditary hemorrhagic telangiectasia – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/hht/diagnosis-treatment/drc-20351136

  If you or your child has HHT, if you can, seek treatment at an HHT Center of Excellence. HHT is a rare condition that is best managed at centers that treat all aspects of this condition at every age. So it can be hard to find a specialist to treat it. […] In the United States, Cure HHT names HHT Centers of Excellence for being able to diagnose and treat all aspects of the condition. Mayo Clinic is an HHT Center of Excellence and cares for many people and their family members diagnosed with HHT. […] Medicines that help stop the bleeding linked with HHT can be divided into three broad groups: […] One treatment for HHT is bevacizumab (Avastin). Avastin goes through a tube in a vein, called intravenous. Other medicines healthcare professionals use to block blood vessel growth include pazopanib (Votrient), pomalidomide (Pomalyst) and tacrolimus (Prograf, Protopic, others).

• #44

  https://haematologica.org/article/view/9810

  Hereditary hemorrhagic telangiectasia (HHT, Osler-Weber-Rendu disease) is a rare multisystem vascular disorder causing chronic gastrointestinal bleeding, epistaxis, and severe anemia. Bevacizumab, an anti-vascular endothelial growth factor antibody, may be effective to treat bleeding in HHT. This international, multicenter, retrospective study evaluated the use of systemic bevacizumab to treat HHT-associated bleeding and anemia at 12 HHT treatment centers. 238 HHT patients received bevacizumab for a median of 12 (range, 1-96) months. Compared with pretreatment, bevacizumab increased mean hemoglobin by 3.2 g/dL (95% CI, 2.9-3.5 g/dL) and decreased the epistaxis severity score (ESS) by 3.4 (3.2-3.7) points during the first year of treatment. Compared with 6 months pretreatment, RBC units transfused decreased by 82% and iron infusions decreased by 70% during the first 6 months of bevacizumab treatment. Bevacizumab was well tolerated: hypertension, fatigue, and proteinuria were the most common adverse events. In conclusion, systemic bevacizumab was safe and effective to manage chronic bleeding and anemia in HHT.

• #45

  https://haematologica.org/article/view/8582

  Management of epistaxis with antifibrinolytic agents is another consideration when preventive measures and local or topical treatments fail. Hyperfibrinolysis contributes to the bleeding phenotype in HHT and antifibrinolytics may work to inhibit fibrinolysis on the telangiectatic wall. […] While the evidence for its use is limited, N-acetylcysteine dosed 600 mg 3 times daily was modestly effective in reducing epistaxis in HHT patients in a pilot study, with the only statistically significant benefit seen in male patients and those with ENG mutations (HHT1). […] Bevacizumab, an anti-VEGF antibody, is a rational therapeutic for HHT as it may reduce excessive angiogenesis. […] A very recent retrospective study by Iyer et al. describes a large cohort of HHT patients receiving bevacizumab to treat GI bleeding and epistaxis. […] Bevacizumab nasal spray has been studied as a treatment for epistaxis. […] In conclusion, HHT is a rare but poorly recognized genetic bleeding disorder that demands greater attention in order to develop targeted and rational management strategies that are both safe and cost-effective.

• #46 Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)

  https://www.upmc.com/services/hht/overview/treatment

  At the HHT Center of Excellence of UPMC and the University of Pittsburgh, our clinical goals are to manage the current symptoms of HHT and to prevent the long-term complications including stroke and brain abscess. […] We also focus on managing bleeding symptoms of HHT, most often in the nose or gastrointestinal (GI) tract. […] Screening for lung and brain vascular malformations is the most important step in preventing neurological problems. […] Nasal bleeding and internal bleeding from the GI tract are the most common sources of chronic HHT symptoms. […] Careful attention to nasal humidification and lubrication is essential in the control of nose bleeding. If this is not effective, our ENT specialists can destroy the vascular malformations with laser surgery. […] After laser surgery, the surgeons may inject a drug called bevacizumab (Avastin) into the malformations to prevent the growth of new vessels.

• #47

  https://haematologica.org/article/view/9810

  Hereditary hemorrhagic telangiectasia (HHT, Osler-Weber-Rendu disease) is a rare multisystem vascular disorder causing chronic gastrointestinal bleeding, epistaxis, and severe anemia. Bevacizumab, an anti-vascular endothelial growth factor antibody, may be effective to treat bleeding in HHT. This international, multicenter, retrospective study evaluated the use of systemic bevacizumab to treat HHT-associated bleeding and anemia at 12 HHT treatment centers. 238 HHT patients received bevacizumab for a median of 12 (range, 1-96) months. Compared with pretreatment, bevacizumab increased mean hemoglobin by 3.2 g/dL (95% CI, 2.9-3.5 g/dL) and decreased the epistaxis severity score (ESS) by 3.4 (3.2-3.7) points during the first year of treatment. Compared with 6 months pretreatment, RBC units transfused decreased by 82% and iron infusions decreased by 70% during the first 6 months of bevacizumab treatment. Bevacizumab was well tolerated: hypertension, fatigue, and proteinuria were the most common adverse events. In conclusion, systemic bevacizumab was safe and effective to manage chronic bleeding and anemia in HHT.

• #48

  https://haematologica.org/article/view/9810

  Hereditary hemorrhagic telangiectasia (HHT, Osler-Weber-Rendu disease) is a rare multisystem vascular disorder causing chronic gastrointestinal bleeding, epistaxis, and severe anemia. Bevacizumab, an anti-vascular endothelial growth factor antibody, may be effective to treat bleeding in HHT. This international, multicenter, retrospective study evaluated the use of systemic bevacizumab to treat HHT-associated bleeding and anemia at 12 HHT treatment centers. 238 HHT patients received bevacizumab for a median of 12 (range, 1-96) months. Compared with pretreatment, bevacizumab increased mean hemoglobin by 3.2 g/dL (95% CI, 2.9-3.5 g/dL) and decreased the epistaxis severity score (ESS) by 3.4 (3.2-3.7) points during the first year of treatment. Compared with 6 months pretreatment, RBC units transfused decreased by 82% and iron infusions decreased by 70% during the first 6 months of bevacizumab treatment. Bevacizumab was well tolerated: hypertension, fatigue, and proteinuria were the most common adverse events. In conclusion, systemic bevacizumab was safe and effective to manage chronic bleeding and anemia in HHT.

• #49 Hereditary hemorrhagic telangiectasia – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/hht/diagnosis-treatment/drc-20351136

  If you or your child has HHT, if you can, seek treatment at an HHT Center of Excellence. HHT is a rare condition that is best managed at centers that treat all aspects of this condition at every age. So it can be hard to find a specialist to treat it. […] In the United States, Cure HHT names HHT Centers of Excellence for being able to diagnose and treat all aspects of the condition. Mayo Clinic is an HHT Center of Excellence and cares for many people and their family members diagnosed with HHT. […] Medicines that help stop the bleeding linked with HHT can be divided into three broad groups: […] One treatment for HHT is bevacizumab (Avastin). Avastin goes through a tube in a vein, called intravenous. Other medicines healthcare professionals use to block blood vessel growth include pazopanib (Votrient), pomalidomide (Pomalyst) and tacrolimus (Prograf, Protopic, others).

• #50 Future treatments for hereditary hemorrhagic telangiectasia | Orphanet Journal of Rare Diseases | Full Text

  https://ojrd.biomedcentral.com/articles/10.1186/s13023-019-1281-4

  Hereditary Hemorrhagic Telangiectasia (HHT), also known as Rendu-Osler syndrome, is a genetic vascular disorder affecting 1 in 5000-8000 individuals worldwide. Presently, the therapeutic treatments for HHT are intended to reduce the symptoms of the disease. However, recent progress has been made using drugs that target VEGF (vascular endothelial growth factor) and the angiogenic pathway with the use of bevacizumab (anti-VEGF antibody). […] Although current treatments succeed pretty well at reducing recurrent epistaxis, there is still a need for magic bullets allowing to revert telangiectasias and AVMs into a normal vasculature and to definitely cure the disease. […] The first randomized phase III clinical trial to study bevacizumab efficiency and safety is now ongoing (NCT 03227263). […] Tacrolimus has been tested in several mouse models for HHT. It was found to decrease the number of retinal arteriovenous malformations induced by BMP9/10-immunodepletion in mice (HHT model).

• #51 Hereditary hemorrhagic telangiectasia – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/hht/diagnosis-treatment/drc-20351136

  If you or your child has HHT, if you can, seek treatment at an HHT Center of Excellence. HHT is a rare condition that is best managed at centers that treat all aspects of this condition at every age. So it can be hard to find a specialist to treat it. […] In the United States, Cure HHT names HHT Centers of Excellence for being able to diagnose and treat all aspects of the condition. Mayo Clinic is an HHT Center of Excellence and cares for many people and their family members diagnosed with HHT. […] Medicines that help stop the bleeding linked with HHT can be divided into three broad groups: […] One treatment for HHT is bevacizumab (Avastin). Avastin goes through a tube in a vein, called intravenous. Other medicines healthcare professionals use to block blood vessel growth include pazopanib (Votrient), pomalidomide (Pomalyst) and tacrolimus (Prograf, Protopic, others).

• #52 Hereditary hemorrhagic telangiectasia – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/hht/diagnosis-treatment/drc-20351136

  If you or your child has HHT, if you can, seek treatment at an HHT Center of Excellence. HHT is a rare condition that is best managed at centers that treat all aspects of this condition at every age. So it can be hard to find a specialist to treat it. […] In the United States, Cure HHT names HHT Centers of Excellence for being able to diagnose and treat all aspects of the condition. Mayo Clinic is an HHT Center of Excellence and cares for many people and their family members diagnosed with HHT. […] Medicines that help stop the bleeding linked with HHT can be divided into three broad groups: […] One treatment for HHT is bevacizumab (Avastin). Avastin goes through a tube in a vein, called intravenous. Other medicines healthcare professionals use to block blood vessel growth include pazopanib (Votrient), pomalidomide (Pomalyst) and tacrolimus (Prograf, Protopic, others).

• #53 Oral medication effective for HHT

  https://consultqd.clevelandclinic.org/pomalidomide-effective-in-treating-hereditary-hemorrhagic-telangiectasia

  Oral medication reduces epistaxis and improves quality of life for patients with rare vascular disorder hereditary hemorrhagic telangiectasia (HHT), for which there currently exists no FDA-approved medications. Patients receiving pomalidomide experienced notable reductions in nosebleed frequency and severity, less reliance on blood and iron transfusions, and improved quality of life. […] Mild cases may be treated with nasal hydration, tranexamic acid or endoscopic ablation, but for systemic manifestations, there are few effective options. […] Pomalidomide is an FDA approved medication for relapsed/refractory multiple myeloma. The pilot study of nine patients showed a clear signal for efficacy, including significant improvements for several of the study participants. […] At that time, the NHLBI requested that the study halt further randomization and enrollment early, due to the unequivocal demonstration of efficacy. […] Quite a few patients who were on the trial have continued on the medication, with the support of the drug manufacturer. A handful who no longer take the medication also continued to experience fewer nosebleeds four to six months after stopping treatment.

• #54 Hereditary hemorrhagic telangiectasia – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/hht/diagnosis-treatment/drc-20351136

  If you or your child has HHT, if you can, seek treatment at an HHT Center of Excellence. HHT is a rare condition that is best managed at centers that treat all aspects of this condition at every age. So it can be hard to find a specialist to treat it. […] In the United States, Cure HHT names HHT Centers of Excellence for being able to diagnose and treat all aspects of the condition. Mayo Clinic is an HHT Center of Excellence and cares for many people and their family members diagnosed with HHT. […] Medicines that help stop the bleeding linked with HHT can be divided into three broad groups: […] One treatment for HHT is bevacizumab (Avastin). Avastin goes through a tube in a vein, called intravenous. Other medicines healthcare professionals use to block blood vessel growth include pazopanib (Votrient), pomalidomide (Pomalyst) and tacrolimus (Prograf, Protopic, others).

• #55 Future treatments for hereditary hemorrhagic telangiectasia | Orphanet Journal of Rare Diseases | Full Text

  https://ojrd.biomedcentral.com/articles/10.1186/s13023-019-1281-4

  Hereditary Hemorrhagic Telangiectasia (HHT), also known as Rendu-Osler syndrome, is a genetic vascular disorder affecting 1 in 5000-8000 individuals worldwide. Presently, the therapeutic treatments for HHT are intended to reduce the symptoms of the disease. However, recent progress has been made using drugs that target VEGF (vascular endothelial growth factor) and the angiogenic pathway with the use of bevacizumab (anti-VEGF antibody). […] Although current treatments succeed pretty well at reducing recurrent epistaxis, there is still a need for magic bullets allowing to revert telangiectasias and AVMs into a normal vasculature and to definitely cure the disease. […] The first randomized phase III clinical trial to study bevacizumab efficiency and safety is now ongoing (NCT 03227263). […] Tacrolimus has been tested in several mouse models for HHT. It was found to decrease the number of retinal arteriovenous malformations induced by BMP9/10-immunodepletion in mice (HHT model).

• #56 Future treatments for hereditary hemorrhagic telangiectasia | Orphanet Journal of Rare Diseases | Full Text

  https://ojrd.biomedcentral.com/articles/10.1186/s13023-019-1281-4

  All these observations prompted us to set up a recent clinical trial to evaluate nasal topical administration of tacrolimus in HHT patients. […] Sirolimus binds FKBP12 and inhibits mTOR (mammalian Target Of Rapamycin), which is downstream of PI3K and AKT, and this could be another mechanism by which this drug targets this pathway. […] It is puzzling however, that no etiological therapeutic treatment targeting the mutated components of the BMP9/10-ALK1-Smad1/5/9 signaling pathway has been developed so far. This review focuses on the possible repositioning of existing drugs that either correct the angiogenic defects of HHT patients (Bevacizumab, tyrosine kinase inhibitors, PI3 Kinase inhibitors) or reactivate the altered BMP9/10 signaling pathway (Tacrolimus, Sirolimus).

• #57 Oral medication effective for HHT

  https://consultqd.clevelandclinic.org/pomalidomide-effective-in-treating-hereditary-hemorrhagic-telangiectasia

  Oral medication reduces epistaxis and improves quality of life for patients with rare vascular disorder hereditary hemorrhagic telangiectasia (HHT), for which there currently exists no FDA-approved medications. Patients receiving pomalidomide experienced notable reductions in nosebleed frequency and severity, less reliance on blood and iron transfusions, and improved quality of life. […] Mild cases may be treated with nasal hydration, tranexamic acid or endoscopic ablation, but for systemic manifestations, there are few effective options. […] Pomalidomide is an FDA approved medication for relapsed/refractory multiple myeloma. The pilot study of nine patients showed a clear signal for efficacy, including significant improvements for several of the study participants. […] At that time, the NHLBI requested that the study halt further randomization and enrollment early, due to the unequivocal demonstration of efficacy. […] Quite a few patients who were on the trial have continued on the medication, with the support of the drug manufacturer. A handful who no longer take the medication also continued to experience fewer nosebleeds four to six months after stopping treatment.

• #58 Osler-Weber-Rendu Disease (Hereditary Hemorrhagic Telangiectasia) Treatment & Management: Approach Considerations, Treatment of Epistaxis, Treatment of Gastrointestinal Bleeding

  https://emedicine.medscape.com/article/2048472-treatment

  In severe cases of HHT, recurrent epistaxis refractory to ablative treatment is treated surgically with nasal septum skin transplants by using skin taken from the lower trunk. Severe cases of HHT may respond to estrogen therapy. […] Control of intermittent gastrointestinal (GI) bleeding may be achieved medically. However, brisk hemorrhage may call for endoscopic treatment or surgical resection. […] Pulmonary hemorrhage may be treated surgically by using silicone balloon tamponade or other means. Embolization (embolotherapy) or surgical resection is indicated for pulmonary AVM if it is localized and accessible, with the goal of limiting the risks of embolic central nervous system (CNS) complications, hemodynamic sequelae, or hemorrhage. […] Hemodynamically significant shunt from hepatic AVM may be treatable with embolization to stabilize heart failure or encephalopathy. Extensive or symptomatic liver disease may warrant evaluation for liver transplantation.

• #59 Hereditary Hemorrhagic Telangiectasia (HHT) | Treatment & Management | Point of Care

  https://www.statpearls.com/point-of-care/141559

  Surgical interventions focused on prevention and reducing severity include electrosurgical plasma coagulation, potassium titanyl phosphate (KTP) laser photocoagulation, and sclerotherapy with sodium tetradecyl sulfate. […] Detection and treatment of asymptomatic PAVM are recommended due to associated neurological risks, including brain abscesses and paradoxical embolic strokes. The mainstay treatment of PAVMs is transcatheter embolization with embolic material such as metallic coils and Amplatzer vascular plugs. […] Management of HAVMs is based on the symptoms and type of complications. HHT patients with HAVMs may have high-output cardiac failure, portal hypertension, or cirrhosis, which are managed medically. […] For HHT patients with symptomatic CAVMs or risk factors, such as a family history of cerebral hemorrhage, treatment options are embolization, microsurgery, stereotactic radiation, or a combination of these modalities.

• #60 Hereditary hemorrhagic telangiectasia – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/hht/diagnosis-treatment/drc-20351136

  Serious nosebleeds are one of the most common signs of HHT. These sometimes happen daily. They can cause so much blood loss that you become anemic. You might need to receive blood, called a transfusion, and iron through an arm vein. […] Procedures to lower the number of nosebleeds and lessen how bad they are may include: […] In this procedure, a healthcare professional threads a long, slender tube through the blood vessels to the AVM. Then the health professional puts in a plug or a metal coil to block blood from entering the AVM. This shrinks and heals the AVM over time. Embolization treats lung and brain AVMs, but not liver AVMs. […] Rarely, treatment for AVMs in the liver is a liver transplant.

• #61 Osler-Weber-Rendu Disease (Hereditary Hemorrhagic Telangiectasia) Treatment & Management: Approach Considerations, Treatment of Epistaxis, Treatment of Gastrointestinal Bleeding

  https://emedicine.medscape.com/article/2048472-treatment

  Localized lesions can be effectively addressed by means of surgical resection. Diffuse multiple AVMs smaller than 1.5 cm can be observed. As with non-HHT AVMs, an enlarging or symptomatic lesion should be resected. […] Embolization has been shown to be effective in closing shunts and should be weighed with surgery as an option for addressing pulmonary AVM. […] Special considerations must be applied in the management of pulmonary AVM in women planning pregnancy; progression of pulmonary shunt and fatal rupture have been described. […] Embolization of the hepatic artery is a potential option for selected patients with liver involvement, as is liver transplantation. […] Liver transplantation may be considered in patients with symptomatic hepatic HHT who present with life-threatening conditions such as hepatobiliary sepsis and severe cardiopulmonary changes. […] Hepatic embolization in patients with extensive liver involvement has been discouraged because of the potential complications of liver parenchymal or biliary necrosis with ensuing sepsis.

• #62 Hereditary haemorrhagic telangiectasia (HHT)

  https://www.nhs.uk/conditions/hereditary-haemorrahagic-telangiectasia/

  Telangiectasia on the skin or in the lining of the nose can sometimes be improved with vascular laser or intense pulsed light (IPL) treatment: for the skin, you’ll usually need a referral to a dermatologist this may be expensive if treatment is not available on the NHS as 2 to 4 treatments a year may be needed; for the nose, you’ll need a referral to an ear, nose and throat (ENT) specialist these treatments are usually available on the NHS. […] AVMs in the body may require specialist treatment. Your HHT specialist will explain any procedures to you in more detail. […] For example, AVMs in the lung are usually treated, even if they’re not causing any apparent problems. They’re treated by embolisation, a procedure that blocks the blood supply to the AVM. A tiny plug is inserted inside the artery supplying the abnormal blood vessel. […] For brain AVMs, embolisation, surgery and stereotactic radiotherapy (precisely delivering radiation to the blood vessel) are possible treatment options.

• #63 Hereditary Hemorrhagic Telangiectasia Center HHT | Stanford Health Care

  https://stanfordhealthcare.org/medical-clinics/hereditary-hemorrhagic-telangiectasia-center-of-excellence.html

  We use laser treatments to manage telangiectases on skin in these sensitive areas. […] Lung AVMs are life-threatening and should be treated even before symptoms appear. We can permanently treat lung AVMs using a minimally invasive procedure known as embolization. During embolization, you receive local anesthesia. The specialist makes a tiny cut in the skin, inserts a catheter into the femoral vein in the groin, and then directs the catheter to the abnormal blood vessels in the lung. Next, synthetic coils are placed in the artery feeding the AVM to permanently block blood flow to the AVM. Patients with a single AVM may be treated on an outpatient basis. Two or more AVMs require inpatient treatment.

• #64 HHT | Symptoms, Diagnosis & Treatment

  https://www.cincinnatichildrens.org/health/h/hht

  – Embolization: In this technique, a doctor inserts a catheter into an artery in your groin. It is then threaded through your arteries into the feeding artery of the AVM. A substance (ex: coil) is then inserted to block blood flow into the AVM. […] – Lobectomy: In this technique, the part of the lung that has the AVM is removed. […] Treatment of Nosebleeds […] – Use of a humidifier […] – Use of a water-based nasal lubricant […] – Possible uses of oral or topical medicines are being investigated […] – Coagulation therapy (laser coagulation, cautery) […] – Surgery (septal dermoplasty, Youngs procedure) […] Treatment of Anemia […] – Oral iron […] – IV iron replacement […] – Red blood cell transfusions […] – IV bevacizumab / avastin

• #65 Hereditary Hemorrhagic Telangiectasia (HHT) (Osler-Weber-Rendu) – MD Searchlight

  https://mdsearchlight.com/genetic-disorders/hereditary-hemorrhagic-telangiectasia-hht-osler-weber-rendu/?utm_source=pubmedlink&utm_campaign=MDS&utm_content=141559

  Patients suffering from iron deficiency and anemia need iron replacement. This can be done via oral or intravenous (IV) iron infusions. Blood transfusions may also be necessary in some situations. As for blood thinners (anticoagulants), they’re allowed in HHT patients, but the type used depends on the patient’s suitability. […] Patients with mild to moderate GI bleeding could be managed with iron replacement. For severe cases, iron replacement and transfusions would be necessary. Severe cases might also need certain drugs and endoscopic procedures. […] PAVMs are recommended to be detected and treated due to their associated complications. The main treatment is a procedure called transcatheter embolization, which helps block the abnormal bleeding in the lungs. CT scans are recommended after the procedure to confirm it was successful.

• #66 Osler-Weber-Rendu Disease (Hereditary Hemorrhagic Telangiectasia) Treatment & Management: Approach Considerations, Treatment of Epistaxis, Treatment of Gastrointestinal Bleeding

  https://emedicine.medscape.com/article/2048472-treatment

  Currently available therapies, including microsurgery, embolization, and radiosurgery, are invasive and associated with considerable adverse effects. No specific medical therapy is available for brain AVM patients. […] For selected CNS lesions, neurosurgical resection may be indicated. Embolotherapy and radiotherapy may be alternative options, depending on lesion morphology. […] Antibiotic prophylaxis should be considered before surgical or dental procedures in all patients with known pulmonary AVMs or positive contrast echocardiography findings (agitated saline solution transthoracic contrast echocardiography [TTCE] grade 1 or higher). […] Studies recommend that women with HHT who conceive should be considered to have high-risk pregnancies because of rare major complications and improved survival outcome following prior recognition.

• #67 Hereditary Hemorrhagic Telangiectasia | Condition | UT Southwestern Medical Center

  https://utswmed.org/conditions-treatments/hereditary-hemorrhagic-telangiectasia/

  UT Southwestern Medical Center is one of 22 designated HHT Centers of Excellence in the United States, with experts in the diagnosis and treatment of hereditary hemorrhagic telangiectasia (HHT). Our Hereditary Hemorrhagic Telangiectasia Center is the leading source for HHT care in the region and the only HHT Center of Excellence in Texas. […] Although there is no cure for HHT, effective treatment can help patients manage the disease and prevent its complications. […] At UT Southwestern, a number of treatment options are available for HHT and related conditions, such as: […] Anemia: Most often caused by iron deficiency, anemia usually responds to oral iron supplements and treatment of nose or GI bleeding. […] Cerebral AVMs: Treatment of cerebral AVMs is individualized. Most small, asymptomatic AVMs will be monitored. For those that require treatment, options include surgery, catheter-guided therapy, and highly localized radiation therapy.

• #68 Osler-Weber-Rendu Disease (Hereditary Hemorrhagic Telangiectasia) Treatment & Management: Approach Considerations, Treatment of Epistaxis, Treatment of Gastrointestinal Bleeding

  https://emedicine.medscape.com/article/2048472-treatment

  Currently available therapies, including microsurgery, embolization, and radiosurgery, are invasive and associated with considerable adverse effects. No specific medical therapy is available for brain AVM patients. […] For selected CNS lesions, neurosurgical resection may be indicated. Embolotherapy and radiotherapy may be alternative options, depending on lesion morphology. […] Antibiotic prophylaxis should be considered before surgical or dental procedures in all patients with known pulmonary AVMs or positive contrast echocardiography findings (agitated saline solution transthoracic contrast echocardiography [TTCE] grade 1 or higher). […] Studies recommend that women with HHT who conceive should be considered to have high-risk pregnancies because of rare major complications and improved survival outcome following prior recognition.

• #69 Hereditary Hemorrhagic Telangiectasia: Diagnosis and Management | AAFP

  https://www.aafp.org/pubs/afp/issues/2010/1001/p785.html

  Pulmonary AVMs can be successfully embolized with coils. […] GI bleeding may be treated locally with laser during endoscopy. […] Cerebral AVMs can be treated with embolization, radiotherapy, or surgery. […] Medical therapies will continue to be a source of interest in treating patients with HHT. Vascular endothelial growth factor inhibitors have shown promise in the treatment of epistaxis and advanced liver disease.

• #70 HHT | Symptoms, Diagnosis & Treatment

  https://www.cincinnatichildrens.org/health/h/hht

  HHT Treatment […] Treatment of AVMs […] Brain AVMs: […] – Observe: Small AVMs are sometimes observed over time for any changes or growth. […] – Surgical excision (removal): This technique is similar to other brain surgeries. The location of the AVM and the risks to removing it help your doctors decide if surgical excision or another treatment is the best option for you. […] – Embolization: In this technique, a doctor inserts a catheter into an artery in your groin. It is then threaded through your arteries into the feeding artery of the AVM. A substance (ex: glue) is then inserted to block blood flow into the AVM. […] – Stereotactic radiosurgery (SRS): Focused radiation is used to destroy the AVM. […] Lung AVMs: […] – Observe: Small AVMs are sometimes observed over time to watch for any changes or growth.

• #71 Hereditary haemorrhagic telangiectasia (HHT)

  https://www.nhs.uk/conditions/hereditary-haemorrahagic-telangiectasia/

  Telangiectasia on the skin or in the lining of the nose can sometimes be improved with vascular laser or intense pulsed light (IPL) treatment: for the skin, you’ll usually need a referral to a dermatologist this may be expensive if treatment is not available on the NHS as 2 to 4 treatments a year may be needed; for the nose, you’ll need a referral to an ear, nose and throat (ENT) specialist these treatments are usually available on the NHS. […] AVMs in the body may require specialist treatment. Your HHT specialist will explain any procedures to you in more detail. […] For example, AVMs in the lung are usually treated, even if they’re not causing any apparent problems. They’re treated by embolisation, a procedure that blocks the blood supply to the AVM. A tiny plug is inserted inside the artery supplying the abnormal blood vessel. […] For brain AVMs, embolisation, surgery and stereotactic radiotherapy (precisely delivering radiation to the blood vessel) are possible treatment options.

• #72 Hereditary haemorrhagic telangiectasia (HHT)

  https://www.nhs.uk/conditions/hereditary-haemorrahagic-telangiectasia/

  Telangiectasia on the skin or in the lining of the nose can sometimes be improved with vascular laser or intense pulsed light (IPL) treatment: for the skin, you’ll usually need a referral to a dermatologist this may be expensive if treatment is not available on the NHS as 2 to 4 treatments a year may be needed; for the nose, you’ll need a referral to an ear, nose and throat (ENT) specialist these treatments are usually available on the NHS. […] AVMs in the body may require specialist treatment. Your HHT specialist will explain any procedures to you in more detail. […] For example, AVMs in the lung are usually treated, even if they’re not causing any apparent problems. They’re treated by embolisation, a procedure that blocks the blood supply to the AVM. A tiny plug is inserted inside the artery supplying the abnormal blood vessel. […] For brain AVMs, embolisation, surgery and stereotactic radiotherapy (precisely delivering radiation to the blood vessel) are possible treatment options.

• #73 HHT | Symptoms, Diagnosis & Treatment

  https://www.cincinnatichildrens.org/health/h/hht

  HHT Treatment […] Treatment of AVMs […] Brain AVMs: […] – Observe: Small AVMs are sometimes observed over time for any changes or growth. […] – Surgical excision (removal): This technique is similar to other brain surgeries. The location of the AVM and the risks to removing it help your doctors decide if surgical excision or another treatment is the best option for you. […] – Embolization: In this technique, a doctor inserts a catheter into an artery in your groin. It is then threaded through your arteries into the feeding artery of the AVM. A substance (ex: glue) is then inserted to block blood flow into the AVM. […] – Stereotactic radiosurgery (SRS): Focused radiation is used to destroy the AVM. […] Lung AVMs: […] – Observe: Small AVMs are sometimes observed over time to watch for any changes or growth.

• #74 Hereditary Hemorrhagic Telangiectasia | Condition | UT Southwestern Medical Center

  https://utswmed.org/conditions-treatments/hereditary-hemorrhagic-telangiectasia/

  UT Southwestern Medical Center is one of 22 designated HHT Centers of Excellence in the United States, with experts in the diagnosis and treatment of hereditary hemorrhagic telangiectasia (HHT). Our Hereditary Hemorrhagic Telangiectasia Center is the leading source for HHT care in the region and the only HHT Center of Excellence in Texas. […] Although there is no cure for HHT, effective treatment can help patients manage the disease and prevent its complications. […] At UT Southwestern, a number of treatment options are available for HHT and related conditions, such as: […] Anemia: Most often caused by iron deficiency, anemia usually responds to oral iron supplements and treatment of nose or GI bleeding. […] Cerebral AVMs: Treatment of cerebral AVMs is individualized. Most small, asymptomatic AVMs will be monitored. For those that require treatment, options include surgery, catheter-guided therapy, and highly localized radiation therapy.

• #75 Hereditary Hemorrhagic Telangiectasia (HHT) (Osler-Weber-Rendu) – MD Searchlight

  https://mdsearchlight.com/genetic-disorders/hereditary-hemorrhagic-telangiectasia-hht-osler-weber-rendu/?utm_source=pubmedlink&utm_campaign=MDS&utm_content=141559

  HAVMs are typically managed according to the symptoms they cause. They could cause problems like cardiac failure, portal hypertension, or cirrhosis, which are all managed medically. However, liver transplantation might be necessary for symptomatic HAVMs that fail to respond to medical treatments. […] CAVMs are usually small and located superficially. However, they’re usually managed conservatively (without intervention) because intervention has a higher risk of stroke or death. If intervention becomes necessary, options include embolization, microsurgery, stereotactic radiation, or a combination of these procedures. The choice of treatment depends on several factors, such as suitability for surgery and the size of the lesion.

• #76 Hereditary Hemorrhagic Telangiectasia (HHT) (Osler-Weber-Rendu) – MD Searchlight

  https://mdsearchlight.com/genetic-disorders/hereditary-hemorrhagic-telangiectasia-hht-osler-weber-rendu/?utm_source=pubmedlink&utm_campaign=MDS&utm_content=141559

  HAVMs are typically managed according to the symptoms they cause. They could cause problems like cardiac failure, portal hypertension, or cirrhosis, which are all managed medically. However, liver transplantation might be necessary for symptomatic HAVMs that fail to respond to medical treatments. […] CAVMs are usually small and located superficially. However, they’re usually managed conservatively (without intervention) because intervention has a higher risk of stroke or death. If intervention becomes necessary, options include embolization, microsurgery, stereotactic radiation, or a combination of these procedures. The choice of treatment depends on several factors, such as suitability for surgery and the size of the lesion.

• #77 Osler-Weber-Rendu Disease (Hereditary Hemorrhagic Telangiectasia) Treatment & Management: Approach Considerations, Treatment of Epistaxis, Treatment of Gastrointestinal Bleeding

  https://emedicine.medscape.com/article/2048472-treatment

  Localized lesions can be effectively addressed by means of surgical resection. Diffuse multiple AVMs smaller than 1.5 cm can be observed. As with non-HHT AVMs, an enlarging or symptomatic lesion should be resected. […] Embolization has been shown to be effective in closing shunts and should be weighed with surgery as an option for addressing pulmonary AVM. […] Special considerations must be applied in the management of pulmonary AVM in women planning pregnancy; progression of pulmonary shunt and fatal rupture have been described. […] Embolization of the hepatic artery is a potential option for selected patients with liver involvement, as is liver transplantation. […] Liver transplantation may be considered in patients with symptomatic hepatic HHT who present with life-threatening conditions such as hepatobiliary sepsis and severe cardiopulmonary changes. […] Hepatic embolization in patients with extensive liver involvement has been discouraged because of the potential complications of liver parenchymal or biliary necrosis with ensuing sepsis.

• #78 Hereditary hemorrhagic telangiectasia – Wikipedia

  https://en.wikipedia.org/wiki/Hereditary_hemorrhagic_telangiectasia

  Lung lesions, once identified, are usually treated to prevent episodes of bleeding and more importantly embolism to the brain. […] The most effective current therapy is embolization with detachable metal coils or plugs. […] Given that liver AVMs generally cause high-output cardiac failure, the emphasis is on treating this with diuretics to reduce the circulating blood volume, restriction of salt and fluid intake, and antiarrhythmic agents in case of irregular heart beat. […] The decision to treat brain arteriovenous malformations depends on the symptoms that they cause (such as seizures or headaches).

• #79 Hereditary hemorrhagic telangiectasia – Wikipedia

  https://en.wikipedia.org/wiki/Hereditary_hemorrhagic_telangiectasia

  Lung lesions, once identified, are usually treated to prevent episodes of bleeding and more importantly embolism to the brain. […] The most effective current therapy is embolization with detachable metal coils or plugs. […] Given that liver AVMs generally cause high-output cardiac failure, the emphasis is on treating this with diuretics to reduce the circulating blood volume, restriction of salt and fluid intake, and antiarrhythmic agents in case of irregular heart beat. […] The decision to treat brain arteriovenous malformations depends on the symptoms that they cause (such as seizures or headaches).

• #80

  https://umiamihealth.org/en/treatments-and-services/interventional-radiology/vascular-disease/hereditary-hemorrhagic-telangiectasia-(hht)

  Treatment for brain vascular malformations in patients with HHT includes brain angiogram, brain embolization, surgical removal, and stereotactic radiosurgery (Gamma Knife). […] Treatment for lung AVMs in patients with HHT includes pulmonary embolization and surgical removal. […] Treatment for liver AVMs in patients with HHT may include Bevacizumab and liver transplant if symptoms or complications arise. […] Treatment for GI bleeding in patients with HHT includes argon plasma coagulation, oral anti-fibrinolytics, Bevacizumab/systemic anti-angiogenic therapy, and management of anemia and iron deficiency. […] If you have HHT, you should be screened for iron deficiency and anemia, take iron replacements/IV infusions, and receive red blood cell transfusion when needed. […] If your child has large AVMs or those associated with symptoms, they should be treated to avoid complications.

• #81 Osler-Weber-Rendu Disease (Hereditary Hemorrhagic Telangiectasia) Treatment & Management: Approach Considerations, Treatment of Epistaxis, Treatment of Gastrointestinal Bleeding

  https://emedicine.medscape.com/article/2048472-treatment

  Localized lesions can be effectively addressed by means of surgical resection. Diffuse multiple AVMs smaller than 1.5 cm can be observed. As with non-HHT AVMs, an enlarging or symptomatic lesion should be resected. […] Embolization has been shown to be effective in closing shunts and should be weighed with surgery as an option for addressing pulmonary AVM. […] Special considerations must be applied in the management of pulmonary AVM in women planning pregnancy; progression of pulmonary shunt and fatal rupture have been described. […] Embolization of the hepatic artery is a potential option for selected patients with liver involvement, as is liver transplantation. […] Liver transplantation may be considered in patients with symptomatic hepatic HHT who present with life-threatening conditions such as hepatobiliary sepsis and severe cardiopulmonary changes. […] Hepatic embolization in patients with extensive liver involvement has been discouraged because of the potential complications of liver parenchymal or biliary necrosis with ensuing sepsis.

• #82 Hereditary hemorrhagic telangiectasia – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/hht/diagnosis-treatment/drc-20351136

  Serious nosebleeds are one of the most common signs of HHT. These sometimes happen daily. They can cause so much blood loss that you become anemic. You might need to receive blood, called a transfusion, and iron through an arm vein. […] Procedures to lower the number of nosebleeds and lessen how bad they are may include: […] In this procedure, a healthcare professional threads a long, slender tube through the blood vessels to the AVM. Then the health professional puts in a plug or a metal coil to block blood from entering the AVM. This shrinks and heals the AVM over time. Embolization treats lung and brain AVMs, but not liver AVMs. […] Rarely, treatment for AVMs in the liver is a liver transplant.

• #83 Osler-Weber-Rendu Disease (Hereditary Hemorrhagic Telangiectasia) Treatment & Management: Approach Considerations, Treatment of Epistaxis, Treatment of Gastrointestinal Bleeding

  https://emedicine.medscape.com/article/2048472-treatment

  Localized lesions can be effectively addressed by means of surgical resection. Diffuse multiple AVMs smaller than 1.5 cm can be observed. As with non-HHT AVMs, an enlarging or symptomatic lesion should be resected. […] Embolization has been shown to be effective in closing shunts and should be weighed with surgery as an option for addressing pulmonary AVM. […] Special considerations must be applied in the management of pulmonary AVM in women planning pregnancy; progression of pulmonary shunt and fatal rupture have been described. […] Embolization of the hepatic artery is a potential option for selected patients with liver involvement, as is liver transplantation. […] Liver transplantation may be considered in patients with symptomatic hepatic HHT who present with life-threatening conditions such as hepatobiliary sepsis and severe cardiopulmonary changes. […] Hepatic embolization in patients with extensive liver involvement has been discouraged because of the potential complications of liver parenchymal or biliary necrosis with ensuing sepsis.

• #84 Hereditary haemorrhagic telangiectasia: diagnosis, screening and management | Medicine Today

  https://medicinetoday.com.au/mt/2023/may/regular-series/hereditary-haemorrhagic-telangiectasia-diagnosis-screening-and-management

  Patients with HHT who are reviewed in a multidisciplinary team clinic are provided with education on nasal care, consisting of the use of regular nasal lubricants, such as petroleum jelly, paw paw-containing ointment or moisturising nasal sprays. […] Management of pulmonary AVMs will depend on their size, symptoms and location and the approaches may include surgery, embolisation or continued surveillance. […] Treatment is often unnecessary for GI AVMs, unless aggressive iron therapy has been ineffective in maintaining haemoglobin concentrations. […] No treatment is recommended for asymptomatic hepatic AVMs. Most symptomatic hepatic AVMs can be satisfactorily managed with intensive medical therapy aimed at improving high-output cardiac failure and hepatic dysfunction. […] Similar to the management of pulmonary AVMs, the management of CNS AVMs will depend on the site, size and symptoms.

• #85 Osler-Weber-Rendu Disease (Hereditary Hemorrhagic Telangiectasia) Treatment & Management: Approach Considerations, Treatment of Epistaxis, Treatment of Gastrointestinal Bleeding

  https://emedicine.medscape.com/article/2048472-treatment

  Endovascular embolization for treatment of severe acute epistaxis is another treatment modality that may be considered. […] N-acetylcysteine has been studied as an option for management of recurrent epistaxis in patients with HHT. […] Multiple case reports have illustrated the use of bevacizumab in the treatment of HHT, and the efficacy of this agent for the management of epistaxis in HHT is being studied. […] Nonoperative treatment of GI bleeding may include the following: Estrogen-progesterone therapy, Transfusion, Aminocaproic acid, Endoscopic photoablation or electrocautery, Bevacizumab. […] A treatment regimen involving intranasal administration of diluted bevacizumab has been shown to be clinically effective in patients with HHT1 and severe GI bleeding. […] Life-threatening GI bleeding can often be effectively treated by means of segmental bowel resection.

• #86 Hereditary Hemorrhagic Telangiectasia: Diagnosis and Management | AAFP

  https://www.aafp.org/pubs/afp/issues/2010/1001/p785.html

  Pulmonary AVMs can be successfully embolized with coils. […] GI bleeding may be treated locally with laser during endoscopy. […] Cerebral AVMs can be treated with embolization, radiotherapy, or surgery. […] Medical therapies will continue to be a source of interest in treating patients with HHT. Vascular endothelial growth factor inhibitors have shown promise in the treatment of epistaxis and advanced liver disease.

• #87 Hereditary Hemorrhagic Telangiectasia | Condition | UT Southwestern Medical Center

  https://utswmed.org/conditions-treatments/hereditary-hemorrhagic-telangiectasia/

  Gastrointestinal (GI) bleeding: GI bleeding might respond to local treatment through an endoscope. A variety of medicines can help reduce bleeding. […] Nosebleeds: Patients with significant nosebleeds will be seen by our otolaryngologist. Therapy will be individualized, and mild nosebleeds can be managed with topical therapy, moisturization, and humidification. Patients with more severe nosebleeds have a complete range of options such as laser therapy, embolization therapy, and surgery. […] Pulmonary AVMs: Most pulmonary AVMs are treated with embolization therapy involving a catheter that enters through the leg; surgery is rarely needed. Most patients will need only one session and will be discharged after several hours. Others might require more than one procedure, and overnight hospitalization is occasionally required. Some AVMs are too small to embolize and will be followed at intervals with CT scans.

• #88

  https://umiamihealth.org/en/treatments-and-services/interventional-radiology/vascular-disease/hereditary-hemorrhagic-telangiectasia-(hht)

  Treatment for brain vascular malformations in patients with HHT includes brain angiogram, brain embolization, surgical removal, and stereotactic radiosurgery (Gamma Knife). […] Treatment for lung AVMs in patients with HHT includes pulmonary embolization and surgical removal. […] Treatment for liver AVMs in patients with HHT may include Bevacizumab and liver transplant if symptoms or complications arise. […] Treatment for GI bleeding in patients with HHT includes argon plasma coagulation, oral anti-fibrinolytics, Bevacizumab/systemic anti-angiogenic therapy, and management of anemia and iron deficiency. […] If you have HHT, you should be screened for iron deficiency and anemia, take iron replacements/IV infusions, and receive red blood cell transfusion when needed. […] If your child has large AVMs or those associated with symptoms, they should be treated to avoid complications.

• #89 Osler-Weber-Rendu Disease (Hereditary Hemorrhagic Telangiectasia) Treatment & Management: Approach Considerations, Treatment of Epistaxis, Treatment of Gastrointestinal Bleeding

  https://emedicine.medscape.com/article/2048472-treatment

  Endovascular embolization for treatment of severe acute epistaxis is another treatment modality that may be considered. […] N-acetylcysteine has been studied as an option for management of recurrent epistaxis in patients with HHT. […] Multiple case reports have illustrated the use of bevacizumab in the treatment of HHT, and the efficacy of this agent for the management of epistaxis in HHT is being studied. […] Nonoperative treatment of GI bleeding may include the following: Estrogen-progesterone therapy, Transfusion, Aminocaproic acid, Endoscopic photoablation or electrocautery, Bevacizumab. […] A treatment regimen involving intranasal administration of diluted bevacizumab has been shown to be clinically effective in patients with HHT1 and severe GI bleeding. […] Life-threatening GI bleeding can often be effectively treated by means of segmental bowel resection.

• #90 Osler-Weber-Rendu Disease (Hereditary Hemorrhagic Telangiectasia) Treatment & Management: Approach Considerations, Treatment of Epistaxis, Treatment of Gastrointestinal Bleeding

  https://emedicine.medscape.com/article/2048472-treatment

  Endovascular embolization for treatment of severe acute epistaxis is another treatment modality that may be considered. […] N-acetylcysteine has been studied as an option for management of recurrent epistaxis in patients with HHT. […] Multiple case reports have illustrated the use of bevacizumab in the treatment of HHT, and the efficacy of this agent for the management of epistaxis in HHT is being studied. […] Nonoperative treatment of GI bleeding may include the following: Estrogen-progesterone therapy, Transfusion, Aminocaproic acid, Endoscopic photoablation or electrocautery, Bevacizumab. […] A treatment regimen involving intranasal administration of diluted bevacizumab has been shown to be clinically effective in patients with HHT1 and severe GI bleeding. […] Life-threatening GI bleeding can often be effectively treated by means of segmental bowel resection.

• #91

  https://www.ejcrim.com/index.php/EJCRIM/article/view/4219

  Hereditary haemorrhagic telangiectasia (HHT) is a rare multi-organ vascular disease. It is characterised by mucocutaneous telangiectasia, epistaxis, and arteriovenous malformations. Some 70% of patients with HHT are thought to have issues with gastrointestinal (GI) bleeding. Traditional management of GI bleeding in HHT includes monitoring for iron deficiency anaemia, iron replacement, antifibrinolytic therapy and control of identifiable bleeding sites with argon photocoagulation during gastrointestinal endoscopy. Blood transfusion may also be required. […] He was commenced on fortnightly bevacizumab (5 mg/kg) for 12 weeks in an attempt to reduce his blood transfusion requirement and manage his anaemia. […] He had a marked improvement in his symptoms within the first month of treatment and did not require any further blood transfusion during the three months of treatment. […] Bevacizumab can be an effective treatment option in patients with HHT refractory to traditional management.

• #92

  https://journals.lww.com/acgcr/fulltext/2019/06000/successful_treatment_of_hereditary_hemorrhagic.10.aspx

  Hereditary hemorrhagic telangiectasia (HHT) is a disorder characterized by telangiectasias and arteriovenous malformations. We present a case report of a 74-year-old man diagnosed with HHT having a favorable response to a somatostatin analogue for treatment. […] Due to insufficient treatment, he was started on subcutaneous octreotide, with significant improvement as evidenced by a steady increase in the hemoglobin level, decreased endoscopic interventions, and decreased blood transfusions, making this the first case of HHT successfully treated with octreotide. […] In limited published case series, somatostatin analogues have been considered in patients with AVMs, which are similar but separate entities from telangiectasias. […] Therefore, although data are limited and a randomized controlled trial does not exist that evaluates the use of octreotide in HHT, octreotide may be useful in patients with chronic gastrointestinal bleeding from vascular abnormalities when endoscopic therapy is insufficient.

• #93

  https://journals.lww.com/acgcr/fulltext/2019/06000/successful_treatment_of_hereditary_hemorrhagic.10.aspx

  This is the first case of telangiectasias in HHT successfully treated with octreotide. […] Given this low rate of side effects and similarity between AVMs and telangiectasias, octreotide is a reasonable drug to try as a primary or adjunctive therapy for bleeding gastrointestinal telangiectasias, especially when other treatments are inadequate. […] Our case report reviews one such case with successful treatment with octreotide, and we propose that further research be explored with randomized control trials within this specific population to determine the long-term effectiveness.

• #94 Osler-Weber-Rendu Disease (Hereditary Hemorrhagic Telangiectasia) Treatment & Management: Approach Considerations, Treatment of Epistaxis, Treatment of Gastrointestinal Bleeding

  https://emedicine.medscape.com/article/2048472-treatment

  Endovascular embolization for treatment of severe acute epistaxis is another treatment modality that may be considered. […] N-acetylcysteine has been studied as an option for management of recurrent epistaxis in patients with HHT. […] Multiple case reports have illustrated the use of bevacizumab in the treatment of HHT, and the efficacy of this agent for the management of epistaxis in HHT is being studied. […] Nonoperative treatment of GI bleeding may include the following: Estrogen-progesterone therapy, Transfusion, Aminocaproic acid, Endoscopic photoablation or electrocautery, Bevacizumab. […] A treatment regimen involving intranasal administration of diluted bevacizumab has been shown to be clinically effective in patients with HHT1 and severe GI bleeding. […] Life-threatening GI bleeding can often be effectively treated by means of segmental bowel resection.

• #95 Hereditary haemorrhagic telangiectasia (HHT)

  https://www.nhs.uk/conditions/hereditary-haemorrahagic-telangiectasia/

  There’s no cure for HHT, but there are effective treatments. […] Some people can be treated by a GP and others need to be under the care of a specialist. […] If you have regular nosebleeds you will probably lose a lot of iron through this loss of blood, especially if you also bleed from telangiectasia in the gut. It may be necessary to replace the lost iron with iron supplements. Dietary changes alone may not be enough. […] People with severe nosebleeds may need emergency nasal packing, where the nose is packed with ribbon gauze or a special nasal sponge. […] Some people may need to see an ear, nose and throat specialist for treatment. Laser therapy may help. […] More severe cases may be treated with skin grafting or other surgery. […] If a lot of blood has been lost from bleeding inside the body or after nosebleeds, a blood transfusion may be needed.

• #96 Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist’s perspective

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6119150/

  Management of epistaxis with antifibrinolytic agents is another consideration when preventive measures and local or topical treatments fail. […] While the evidence for its use is limited, N-acetylcysteine dosed 600 mg 3 times daily was modestly effective in reducing epistaxis in HHT patients in a pilot study, with the only statistically significant benefit seen in male patients and those with ENG mutations (HHT1). […] The development of anemia can have significant consequences for the patient with HHT. […] Estrogen and progestins (e.g. ethinyl estradiol, norethindrone or mestranol) have been used in HHT patients to reduce bleeding complications. […] Anti-VEGF therapies are relatively new for patients with HHT, and their use has been increasing. […] Bevacizumab, an anti-VEGF antibody, is a rational therapeutic for HHT as it may reduce excessive angiogenesis.

• #97 Hereditary hemorrhagic telangiectasia – Wikipedia

  https://en.wikipedia.org/wiki/Hereditary_hemorrhagic_telangiectasia

  Chronic nosebleeds and digestive tract bleeding can both lead to anemia; if the bleeding itself cannot be completely stopped, the anemia requires treatment with iron supplements. Those who cannot tolerate iron tablets or solutions may require administration of intravenous iron, and blood transfusion if the anemia is causing severe symptoms that warrant rapid improvement of the blood count. […] An acute nosebleed may be managed with a variety of measures, such as packing of the nasal cavity with absorbent swabs or gels. […] Frequent nosebleeds can be prevented in part by keeping the nostrils moist, and by applying saline solution, estrogen-containing creams or tranexamic acid; these have few side effects and may have a small degree of benefit. […] Sclerotherapy is another option to manage the bleeding. This process involves injecting a small amount of an aerated irritant (detergent such as sodium tetradecyl sulfate) directly into the telangiectasias.

• #98 Treatment of HHT – CureHHT

  https://curehht.org/understanding-hht/diagnosis-treatment/treatment-of-hht/

  The recommended treatment for AVMs depends almost entirely on the size of the malformation and its location in the body. […] If treatment is required, it is essential that an HHT Center physician is consulted regarding the best option. […] When necessary, intestinal AVMs can be treated by laser, tranexamic acid, IV Avastin and other angiogenesis inhibitors. […] Spinal AVMs are rare, but if detected embolization and surgical treatments are effective in treating spinal AVMs. […] People with HHT who suffer from bleeding should be routinely screened for iron deficiency. It is important that iron deficiency be treated aggressively, by replacing the iron stores in the body. […] In individuals with severe iron deficiency anemia or frequent/severe bleeding, oral iron may not be enough to restore iron stores. In these cases, it is important that treatment with IV iron be considered. […] A blood transfusion provides the part or parts of blood that you need to replenish due to blood loss. Red blood cells (RBC) are the most commonly used type of blood transfusion in the treatment of HHT patients (as well as in the general population).

• #99 HHT | Symptoms, Diagnosis & Treatment

  https://www.cincinnatichildrens.org/health/h/hht

  – Embolization: In this technique, a doctor inserts a catheter into an artery in your groin. It is then threaded through your arteries into the feeding artery of the AVM. A substance (ex: coil) is then inserted to block blood flow into the AVM. […] – Lobectomy: In this technique, the part of the lung that has the AVM is removed. […] Treatment of Nosebleeds […] – Use of a humidifier […] – Use of a water-based nasal lubricant […] – Possible uses of oral or topical medicines are being investigated […] – Coagulation therapy (laser coagulation, cautery) […] – Surgery (septal dermoplasty, Youngs procedure) […] Treatment of Anemia […] – Oral iron […] – IV iron replacement […] – Red blood cell transfusions […] – IV bevacizumab / avastin

• #100 Treatment of HHT – CureHHT

  https://curehht.org/understanding-hht/diagnosis-treatment/treatment-of-hht/

  The recommended treatment for AVMs depends almost entirely on the size of the malformation and its location in the body. […] If treatment is required, it is essential that an HHT Center physician is consulted regarding the best option. […] When necessary, intestinal AVMs can be treated by laser, tranexamic acid, IV Avastin and other angiogenesis inhibitors. […] Spinal AVMs are rare, but if detected embolization and surgical treatments are effective in treating spinal AVMs. […] People with HHT who suffer from bleeding should be routinely screened for iron deficiency. It is important that iron deficiency be treated aggressively, by replacing the iron stores in the body. […] In individuals with severe iron deficiency anemia or frequent/severe bleeding, oral iron may not be enough to restore iron stores. In these cases, it is important that treatment with IV iron be considered. […] A blood transfusion provides the part or parts of blood that you need to replenish due to blood loss. Red blood cells (RBC) are the most commonly used type of blood transfusion in the treatment of HHT patients (as well as in the general population).

• #101 Treatment of HHT | Hereditary Haemorrhagic Telangiectasia

  https://hhtireland.org/treatment/

  Procedures to treat liver AVMs can be very invasive and have the potential to worsen the condition of the patient if an HHT specialist is not involved. […] 90% of HHT patients experience epistaxis (nose bleeding). However, the severity, frequency and duration vary from patient to patient and family member to family member. There is no one treatment that works for everyone. […] Some treatments that are on offer are as follows: […] AVMs are also common in the GI Tract, usually in the stomach and upper portion of the small intestine. When necessary, intestinal AVMs can be treated by laser, tranexamic acid, IV Avastin and other angiogenesis inhibitors. […] A haematologist may consider intravenous (IV) iron if a patient is intolerant of oral iron or has ongoing blood loss.

• #102 Treatment of HHT – CureHHT

  https://curehht.org/understanding-hht/diagnosis-treatment/treatment-of-hht/

  The recommended treatment for AVMs depends almost entirely on the size of the malformation and its location in the body. […] If treatment is required, it is essential that an HHT Center physician is consulted regarding the best option. […] When necessary, intestinal AVMs can be treated by laser, tranexamic acid, IV Avastin and other angiogenesis inhibitors. […] Spinal AVMs are rare, but if detected embolization and surgical treatments are effective in treating spinal AVMs. […] People with HHT who suffer from bleeding should be routinely screened for iron deficiency. It is important that iron deficiency be treated aggressively, by replacing the iron stores in the body. […] In individuals with severe iron deficiency anemia or frequent/severe bleeding, oral iron may not be enough to restore iron stores. In these cases, it is important that treatment with IV iron be considered. […] A blood transfusion provides the part or parts of blood that you need to replenish due to blood loss. Red blood cells (RBC) are the most commonly used type of blood transfusion in the treatment of HHT patients (as well as in the general population).

• #103 Hereditary haemorrhagic telangiectasia (HHT)

  https://www.nhs.uk/conditions/hereditary-haemorrahagic-telangiectasia/

  There’s no cure for HHT, but there are effective treatments. […] Some people can be treated by a GP and others need to be under the care of a specialist. […] If you have regular nosebleeds you will probably lose a lot of iron through this loss of blood, especially if you also bleed from telangiectasia in the gut. It may be necessary to replace the lost iron with iron supplements. Dietary changes alone may not be enough. […] People with severe nosebleeds may need emergency nasal packing, where the nose is packed with ribbon gauze or a special nasal sponge. […] Some people may need to see an ear, nose and throat specialist for treatment. Laser therapy may help. […] More severe cases may be treated with skin grafting or other surgery. […] If a lot of blood has been lost from bleeding inside the body or after nosebleeds, a blood transfusion may be needed.

• #104 Treatment of HHT – CureHHT

  https://curehht.org/understanding-hht/diagnosis-treatment/treatment-of-hht/

  The recommended treatment for AVMs depends almost entirely on the size of the malformation and its location in the body. […] If treatment is required, it is essential that an HHT Center physician is consulted regarding the best option. […] When necessary, intestinal AVMs can be treated by laser, tranexamic acid, IV Avastin and other angiogenesis inhibitors. […] Spinal AVMs are rare, but if detected embolization and surgical treatments are effective in treating spinal AVMs. […] People with HHT who suffer from bleeding should be routinely screened for iron deficiency. It is important that iron deficiency be treated aggressively, by replacing the iron stores in the body. […] In individuals with severe iron deficiency anemia or frequent/severe bleeding, oral iron may not be enough to restore iron stores. In these cases, it is important that treatment with IV iron be considered. […] A blood transfusion provides the part or parts of blood that you need to replenish due to blood loss. Red blood cells (RBC) are the most commonly used type of blood transfusion in the treatment of HHT patients (as well as in the general population).

• #105 Hereditary haemorrhagic telangiectasia (HHT)

  https://www.nhs.uk/conditions/hereditary-haemorrahagic-telangiectasia/

  Telangiectasia on the skin or in the lining of the nose can sometimes be improved with vascular laser or intense pulsed light (IPL) treatment: for the skin, you’ll usually need a referral to a dermatologist this may be expensive if treatment is not available on the NHS as 2 to 4 treatments a year may be needed; for the nose, you’ll need a referral to an ear, nose and throat (ENT) specialist these treatments are usually available on the NHS. […] AVMs in the body may require specialist treatment. Your HHT specialist will explain any procedures to you in more detail. […] For example, AVMs in the lung are usually treated, even if they’re not causing any apparent problems. They’re treated by embolisation, a procedure that blocks the blood supply to the AVM. A tiny plug is inserted inside the artery supplying the abnormal blood vessel. […] For brain AVMs, embolisation, surgery and stereotactic radiotherapy (precisely delivering radiation to the blood vessel) are possible treatment options.

• #106 Treatment of the Mucocutaneous Manifestations of Hereditary Hemorrhagic Telangiectasia Using the Nd:YAG Laser (1064nm) | Actas Dermo-Sifiliográficas

  https://www.actasdermo.org/en-treatment-mucocutaneous-manifestations-hereditary-hemorrhagic-articulo-S1578219016000159

  Osler-Weber-Rendu disease, otherwise known as hereditary hemorrhagic telangiectasia (HHT), is characterized by the presence of epistaxis and multiple mucocutaneous telangiectases in association with arteriovenous malformations affecting different organs, including the lungs, the gastrointestinal system, and the central nervous system. […] Mucocutaneous telangiectases are the most evident sign of HHT. Apart from being cosmetically bothersome, these lesions can cause bleeding and have a considerable impact on quality of life in 27% of cases. […] In this study, we describe our experience with the use of a long-pulse Nd:YAG laser to treat mucocutaneous manifestations of HHT. […] The treatment achieved considerable clearance of both skin and mucosal lesions in few sessions (mean, 2.2 sessions; range, 1-7 sessions), and there were no notable adverse effects such as scarring, persistent purpura, or dyschromia.

• #107 Hereditary Hemorrhagic Telangiectasia (HHT) Treatment | University of Michigan Health

  https://www.uofmhealth.org/conditions-treatments/ear-nose-throat/hereditary-hemorrhagic-telangiectasia-hht-treatment

  Cardiologists and heart failure specialists may see a subset of HHT patients, usually older patients, who may have developed some congestive heart failure related to HHT, vascular malformations, or liver involvement by HHT. […] Our cosmetic dermatologists are called upon to treat skin telangiectasias and other vascular skin lesions, often with laser treatments, for cosmetic reasons or to reduce bleeding from skin lesions. […] Radiation oncologists may be asked to assess and treat patients brain vascular malformations with radiation therapy or gamma knife, for instance, instead of surgery. […] We encourage patients to have their HHT mutation identified by genetic testing, because it may affect treatment recommendations and also makes it easier to test other family members or newborn relatives. […] Liver specialists are occasionally called upon for patients with uncommon yet significant liver involvement with large AVMs. […] Very rarely patients have severe liver AVMs.

• #108 Hereditary haemorrhagic telangiectasia (HHT)

  https://www.nhs.uk/conditions/hereditary-haemorrahagic-telangiectasia/

  Telangiectasia on the skin or in the lining of the nose can sometimes be improved with vascular laser or intense pulsed light (IPL) treatment: for the skin, you’ll usually need a referral to a dermatologist this may be expensive if treatment is not available on the NHS as 2 to 4 treatments a year may be needed; for the nose, you’ll need a referral to an ear, nose and throat (ENT) specialist these treatments are usually available on the NHS. […] AVMs in the body may require specialist treatment. Your HHT specialist will explain any procedures to you in more detail. […] For example, AVMs in the lung are usually treated, even if they’re not causing any apparent problems. They’re treated by embolisation, a procedure that blocks the blood supply to the AVM. A tiny plug is inserted inside the artery supplying the abnormal blood vessel. […] For brain AVMs, embolisation, surgery and stereotactic radiotherapy (precisely delivering radiation to the blood vessel) are possible treatment options.

• #109 Hereditary Hemorrhagic Telangiectasia (HHT) Treatment | ColumbiaDoctors

  https://www.columbiadoctors.org/specialties/lung-breathing-disorders/our-services/hereditary-hemorrhagic-telangiectasia-hht/diagnosis-and-treatment-columbia

  AVMs in the lungs are treated by an interventional radiologist. The procedure is called pulmonary AVM embolization, and is usually performed as a same-day outpatient procedure. Embolization can also be used for AVMs in the brain. […] Because HHT causes bleeding, we will routinely monitor your iron levels. Many people with HHT suffer from low iron, which can be treated by eating high-iron food and taking iron supplements. If your iron deficiency is severe, you may be given iron intravenously (through the vein). In some cases, a blood transfusion may also be necessary. […] If your telangiectasia require treatment, we will refer you to our dermatologist, who uses electrodessication to treat this condition. Electrodessication is an office procedure in which an electric current is used to remove specific skin lesions.

• #110 Hereditary Hemorrhagic Telangiectasia (HHT) | Boston Medical Center

  https://www.bmc.org/patient-care/conditions-we-treat/db/hereditary-hemorrhagic-telangiectasia-hht

  HHT telangiectasias can be treated with a pulsed dye laser, which targets blood vessels, or simple cautery. These procedures can be painful, so sensitive and younger patients may benefit from numbing anesthetic cream 30-120 minutes before the procedure. Treatment often requires more than one session.

• #111 Treatment of the Mucocutaneous Manifestations of Hereditary Hemorrhagic Telangiectasia Using the Nd:YAG Laser (1064nm) | Actas Dermo-Sifiliográficas

  https://www.actasdermo.org/en-treatment-mucocutaneous-manifestations-hereditary-hemorrhagic-articulo-S1578219016000159

  Osler-Weber-Rendu disease, otherwise known as hereditary hemorrhagic telangiectasia (HHT), is characterized by the presence of epistaxis and multiple mucocutaneous telangiectases in association with arteriovenous malformations affecting different organs, including the lungs, the gastrointestinal system, and the central nervous system. […] Mucocutaneous telangiectases are the most evident sign of HHT. Apart from being cosmetically bothersome, these lesions can cause bleeding and have a considerable impact on quality of life in 27% of cases. […] In this study, we describe our experience with the use of a long-pulse Nd:YAG laser to treat mucocutaneous manifestations of HHT. […] The treatment achieved considerable clearance of both skin and mucosal lesions in few sessions (mean, 2.2 sessions; range, 1-7 sessions), and there were no notable adverse effects such as scarring, persistent purpura, or dyschromia.

• #112 Treatment of the Mucocutaneous Manifestations of Hereditary Hemorrhagic Telangiectasia Using the Nd:YAG Laser (1064nm) | Actas Dermo-Sifiliográficas

  https://www.actasdermo.org/en-treatment-mucocutaneous-manifestations-hereditary-hemorrhagic-articulo-S1578219016000159

  Nd:YAG laser therapy is an effective treatment for mucocutaneous telangiectases in patients with HHT. In our series, excellent results were obtained with few sessions and no remarkable adverse effects. However, due to the natural course of the disease, patients should be followed and new lesions retreated as necessary.

• #113 Osler-Weber-Rendu Disease (Hereditary Hemorrhagic Telangiectasia) Treatment & Management: Approach Considerations, Treatment of Epistaxis, Treatment of Gastrointestinal Bleeding

  https://emedicine.medscape.com/article/2048472-treatment

  Currently available therapies, including microsurgery, embolization, and radiosurgery, are invasive and associated with considerable adverse effects. No specific medical therapy is available for brain AVM patients. […] For selected CNS lesions, neurosurgical resection may be indicated. Embolotherapy and radiotherapy may be alternative options, depending on lesion morphology. […] Antibiotic prophylaxis should be considered before surgical or dental procedures in all patients with known pulmonary AVMs or positive contrast echocardiography findings (agitated saline solution transthoracic contrast echocardiography [TTCE] grade 1 or higher). […] Studies recommend that women with HHT who conceive should be considered to have high-risk pregnancies because of rare major complications and improved survival outcome following prior recognition.

• #114 Frequently Asked Questions about Hereditary Hemorrhagic Telangiectasia (HHT)

  https://www.upmc.com/services/hht/frequently-asked-questions

  Yes. As long as we find and treat any lung or brain AVMs, people with HHT have a normal life expectancy. […] Before getting pregnant, you should have a screening for lung and brain AVMs and, if present, have them treated. […] We urge treatment of lung AVMs prior to delivery. […] If you have lung AVMs even if you’ve had treatment be sure to take antibiotics prior to dental procedures (including routine cleaning). […] Finally, people with HHT should avoid scuba diving due to stroke risk from air emboli.

• #115 Osler-Weber-Rendu Disease (Hereditary Hemorrhagic Telangiectasia) Treatment & Management: Approach Considerations, Treatment of Epistaxis, Treatment of Gastrointestinal Bleeding

  https://emedicine.medscape.com/article/2048472-treatment

  Currently available therapies, including microsurgery, embolization, and radiosurgery, are invasive and associated with considerable adverse effects. No specific medical therapy is available for brain AVM patients. […] For selected CNS lesions, neurosurgical resection may be indicated. Embolotherapy and radiotherapy may be alternative options, depending on lesion morphology. […] Antibiotic prophylaxis should be considered before surgical or dental procedures in all patients with known pulmonary AVMs or positive contrast echocardiography findings (agitated saline solution transthoracic contrast echocardiography [TTCE] grade 1 or higher). […] Studies recommend that women with HHT who conceive should be considered to have high-risk pregnancies because of rare major complications and improved survival outcome following prior recognition.

• #116 Hereditary Hemorrhagic Telangiectasia (HHT) Treatment

  https://pulmonaryhypertensionrn.com/pulmonary-hypertension-treatments/hereditary-hemorrhagic-telangiectasia-hht-treatment/

  When identified these are generally treated either with a catheter-based embolization procedure or brain surgery to remove the aneurysm. […] There is clear data in the literature that these abnormal blood vessels should not be treated with embolization. […] An important difference is that we generally avoid blood thinners due to the increased risk of bleeding. […] Oral iron pills are a first line but many patients require periodic intravenous iron infusions. […] Women with HHT who become pregnant are at increased risk of complications and should be managed by a multidisciplinary team with experience in HHT and the complications of HHT.

• #117 Management of Hereditary Hemorrhagic Telangiectasialogo-32logo-40logo-60NEJM Journal WatchnejmJW_1L_RGB-b

  https://www.jwatch.org/na52401/2020/10/01/management-hereditary-hemorrhagic-telangiectasia

  Moisturizing topical therapy is suggested as a first-line treatment for HHT-associated epistaxis, followed by oral tranexamic acid and ablative therapies as second-line options; antiangiogenic agents are offered should the above measures fail to control epistaxis. […] In patients with suspected gastrointestinal bleeding (GIB), endoscopy should be done in centers with HHT expertise; mild GIB can be managed with oral antifibrinolytics, whereas moderate to severe GIB should be managed with systemic antiangiogenic agents. […] In patients who have an indication for antiplatelet or anticoagulant therapy, HHT does not pose an absolute contraindication, though use of direct oral anticoagulants are discouraged. […] Patients aged 15 and older with SMAD-4 HHT should undergo early colon cancer screening.

• #118 Osler-Weber-Rendu Disease (Hereditary Hemorrhagic Telangiectasia) Treatment & Management: Approach Considerations, Treatment of Epistaxis, Treatment of Gastrointestinal Bleeding

  https://emedicine.medscape.com/article/2048472-treatment

  Although estrogen-related hormones and antifibrinolytic agents are commonly used to manage bleeding, some studies suggest that this probably increases the risk of thrombotic events in OWRD patients with pulmonary AVMs. Accordingly, patients should undergo screening for the presence of pulmonary AVMs before treatment is started. […] Pulsed dye laser treatment may be used to photocoagulate telangiectasias in the nasal mucosa. As many as three subsequent treatments may be necessary before any change in bleeding frequency or severity is observed. […] A small prospective randomized trial (26 patients) from Germany of topical estrogen (0.5 mg of 0.1% estriol ointment twice daily) after argon beam coagulation in HHT patients with recurrent epistaxis suggested improved outcome over argon beam coagulation with application of ointment.

• #119 Management of Hereditary Hemorrhagic Telangiectasialogo-32logo-40logo-60NEJM Journal WatchnejmJW_1L_RGB-b

  https://www.jwatch.org/na52401/2020/10/01/management-hereditary-hemorrhagic-telangiectasia

  Moisturizing topical therapy is suggested as a first-line treatment for HHT-associated epistaxis, followed by oral tranexamic acid and ablative therapies as second-line options; antiangiogenic agents are offered should the above measures fail to control epistaxis. […] In patients with suspected gastrointestinal bleeding (GIB), endoscopy should be done in centers with HHT expertise; mild GIB can be managed with oral antifibrinolytics, whereas moderate to severe GIB should be managed with systemic antiangiogenic agents. […] In patients who have an indication for antiplatelet or anticoagulant therapy, HHT does not pose an absolute contraindication, though use of direct oral anticoagulants are discouraged. […] Patients aged 15 and older with SMAD-4 HHT should undergo early colon cancer screening.

• #120 Frequently Asked Questions about Hereditary Hemorrhagic Telangiectasia (HHT)

  https://www.upmc.com/services/hht/frequently-asked-questions

  Yes. As long as we find and treat any lung or brain AVMs, people with HHT have a normal life expectancy. […] Before getting pregnant, you should have a screening for lung and brain AVMs and, if present, have them treated. […] We urge treatment of lung AVMs prior to delivery. […] If you have lung AVMs even if you’ve had treatment be sure to take antibiotics prior to dental procedures (including routine cleaning). […] Finally, people with HHT should avoid scuba diving due to stroke risk from air emboli.

• #121 Hereditary hemorrhagic telangiectasia: MedlinePlus Medical EncyclopediaLock

  https://medlineplus.gov/ency/article/000837.htm

  Treatments may include: […] Surgery to treat bleeding in some areas […] Electrocautery (heating tissue with electricity) or laser surgery to treat frequent or heavy nosebleeds […] Endovascular embolization (injecting a substance through a thin tube) to treat abnormal blood vessels in the brain and other parts of the body […] Some people respond to estrogen therapy, which can reduce bleeding episodes. Iron may also be given if there is a lot of blood loss, leading to anemia. Avoid taking blood-thinning medicines. Some medicines that affect blood vessel development are being studied as possible future treatments. […] Some people may need to take antibiotics before having dental work or surgery. People with lung AVMs should avoid scuba diving to prevent decompression sickness (the bends). Ask your provider what other precautions you should take.

• #122 Osler-Weber-Rendu Disease (Hereditary Hemorrhagic Telangiectasia) Treatment & Management: Approach Considerations, Treatment of Epistaxis, Treatment of Gastrointestinal Bleeding

  https://emedicine.medscape.com/article/2048472-treatment

  Currently available therapies, including microsurgery, embolization, and radiosurgery, are invasive and associated with considerable adverse effects. No specific medical therapy is available for brain AVM patients. […] For selected CNS lesions, neurosurgical resection may be indicated. Embolotherapy and radiotherapy may be alternative options, depending on lesion morphology. […] Antibiotic prophylaxis should be considered before surgical or dental procedures in all patients with known pulmonary AVMs or positive contrast echocardiography findings (agitated saline solution transthoracic contrast echocardiography [TTCE] grade 1 or higher). […] Studies recommend that women with HHT who conceive should be considered to have high-risk pregnancies because of rare major complications and improved survival outcome following prior recognition.

• #123 Frequently Asked Questions about Hereditary Hemorrhagic Telangiectasia (HHT)

  https://www.upmc.com/services/hht/frequently-asked-questions

  Yes. As long as we find and treat any lung or brain AVMs, people with HHT have a normal life expectancy. […] Before getting pregnant, you should have a screening for lung and brain AVMs and, if present, have them treated. […] We urge treatment of lung AVMs prior to delivery. […] If you have lung AVMs even if you’ve had treatment be sure to take antibiotics prior to dental procedures (including routine cleaning). […] Finally, people with HHT should avoid scuba diving due to stroke risk from air emboli.

• #124 Raising Awareness for Hereditary Hemorrhagic Telangiectasia (HHT) at UCSF | UCSF Radiology

  https://radiology.ucsf.edu/blog/raising-awareness-hereditary-hemorrhagic-telangiectasia-hht-ucsf

  HHT is a genetic disorder characterized by abnormal blood vessel growth. These lesions typically appear in the brain, lungs, liver, and gastrointestinal tract, and can cause sudden stroke, heart failure, and pulmonary hypertension if untreated. […] The complexities of HHT require a comprehensive and versatile approach to care. […] The HHT clinic also conducts regular follow-up with patients, conducting imaging studies every one to five years to monitor the progression of lesions. […] This holistic approach aims to provide continuous and tailored care to each patient and contributes to HHT Centers of Excellence demonstrating positive patient outcomes such as fewer hospitalizations, less loss of life, and higher quality of life. […] UCSFs HHT Center of Excellence stands out, with a multidisciplinary team of diagnostic interventional and neurointerventional radiologists, cardiologists, hepatologists, dermatologists, hematologists, neurologists, otolaryngologists, pulmonologists, and neurosurgeons dedicated to addressing the diverse challenges posed by HHT.

• #125 Management of Hereditary Hemorrhagic Telangiectasialogo-32logo-40logo-60NEJM Journal WatchnejmJW_1L_RGB-b

  https://www.jwatch.org/na52401/2020/10/01/management-hereditary-hemorrhagic-telangiectasia

  Moisturizing topical therapy is suggested as a first-line treatment for HHT-associated epistaxis, followed by oral tranexamic acid and ablative therapies as second-line options; antiangiogenic agents are offered should the above measures fail to control epistaxis. […] In patients with suspected gastrointestinal bleeding (GIB), endoscopy should be done in centers with HHT expertise; mild GIB can be managed with oral antifibrinolytics, whereas moderate to severe GIB should be managed with systemic antiangiogenic agents. […] In patients who have an indication for antiplatelet or anticoagulant therapy, HHT does not pose an absolute contraindication, though use of direct oral anticoagulants are discouraged. […] Patients aged 15 and older with SMAD-4 HHT should undergo early colon cancer screening.

• #126 Hereditary Hemorrhagic Telangiectasia (HHT) Center

  https://www.massgeneral.org/medicine/pulmonary/treatments-and-services/hht

  Hereditary Hemorrhagic Telangiectasia (HHT) Center offers compassionate, family-centered multidisciplinary care. We strive to create an “HHT medical home” by offering a wide range of specialists, education and treatments. […] The Mass General HHT Center offers diagnosis, genetic counseling, advanced and cutting-edge therapies, multidisciplinary evaluations and care coordination for people with this common (1 in 5000) genetic condition, and emphasizes the importance of the first step of making the correct diagnosis. […] The Mass General HHT Center is recognized worldwide for our clinical and research excellence, and is certified an HHT Center of Excellence by the Cure HHT Foundation. […] To better understand HHT and offer new treatments, we are involved in many research studies. […] You may have the opportunity to participate in one of these cutting-edge studies, which offer new and promising therapies to treat bleeding, anemia, and other HHT manifestations. […] For interest in new medical treatment options in HHT, please schedule an appointment with Hanny Al-Samkari, MD, in hematology, and inform the scheduler you have HHT and would like to be evaluated for a clinical trial of a new treatment.

• #127 Future treatments for hereditary hemorrhagic telangiectasia | Orphanet Journal of Rare Diseases | Full Text

  https://ojrd.biomedcentral.com/articles/10.1186/s13023-019-1281-4

  Hereditary Hemorrhagic Telangiectasia (HHT), also known as Rendu-Osler syndrome, is a genetic vascular disorder affecting 1 in 5000-8000 individuals worldwide. Presently, the therapeutic treatments for HHT are intended to reduce the symptoms of the disease. However, recent progress has been made using drugs that target VEGF (vascular endothelial growth factor) and the angiogenic pathway with the use of bevacizumab (anti-VEGF antibody). […] Although current treatments succeed pretty well at reducing recurrent epistaxis, there is still a need for magic bullets allowing to revert telangiectasias and AVMs into a normal vasculature and to definitely cure the disease. […] The first randomized phase III clinical trial to study bevacizumab efficiency and safety is now ongoing (NCT 03227263). […] Tacrolimus has been tested in several mouse models for HHT. It was found to decrease the number of retinal arteriovenous malformations induced by BMP9/10-immunodepletion in mice (HHT model).

• #128

  https://www.jci.org/articles/view/176379

  Hereditary hemorrhagic telangiectasia (HHT) is an inherited vascular disorder with highly variable expressivity, affecting up to 1 in 5,000 individuals. […] This Review presents up-to-date insights on this mutated signaling pathway and its crosstalk with proangiogenic pathways, in particular the VEGF pathway, that has allowed the repurposing of new drugs for HHT treatment. […] However, despite the substantial benefits of these new treatments in terms of alleviating symptom severity, this not-so-uncommon bleeding disorder still currently lacks any FDA- or European Medicines Agency-approved (EMA-approved) therapies. […] Awareness of the beneficial effect of blocking VEGF signaling in HHT patients dates back to 2006, when an HHT patient suffering from a malignant mesothelioma unexpectedly showed amelioration of HHT symptoms following antiangiogenic cancer treatment with an anti-VEGF-A monoclonal antibody (bevacizumab).

• #129

  https://www.jci.org/articles/view/176379

  Hereditary hemorrhagic telangiectasia (HHT) is an inherited vascular disorder with highly variable expressivity, affecting up to 1 in 5,000 individuals. […] This Review presents up-to-date insights on this mutated signaling pathway and its crosstalk with proangiogenic pathways, in particular the VEGF pathway, that has allowed the repurposing of new drugs for HHT treatment. […] However, despite the substantial benefits of these new treatments in terms of alleviating symptom severity, this not-so-uncommon bleeding disorder still currently lacks any FDA- or European Medicines Agency-approved (EMA-approved) therapies. […] Awareness of the beneficial effect of blocking VEGF signaling in HHT patients dates back to 2006, when an HHT patient suffering from a malignant mesothelioma unexpectedly showed amelioration of HHT symptoms following antiangiogenic cancer treatment with an anti-VEGF-A monoclonal antibody (bevacizumab).

• #130

  https://www.jci.org/articles/view/176379

  A few years later, the first clinical trial using bevacizumab showed very positive results on 25 patients suffering from HHT. […] Today, with our current knowledge of the pathophysiological mechanisms of HHT owing to preclinical models and clinical trials, the main therapeutic lines of action to be considered include the following: first, avoiding angiogenic and inflammatory stimuli by all means, in line with the second hit hypothesis. […] Another important point is moving toward personalized medicine for each patient. […] It is therefore essential to monitor clinical improvement as a function of bevacizumab levels during maintenance therapy in order to maintain bioactive levels within the therapeutic window, especially if efficacy appears to be declining. […] Another aspect that should be considered more carefully is tailoring treatment to disease severity in order to limit drug toxicity.

• #131

  https://www.jci.org/articles/view/176379

  Although great progress has been made in the treatment of HHT patients, there are still some remaining challenges. […] Thus there is a real need for testing the efficacy of drugs in preclinical models on large AVMs or AVMs at adult stages. […] In the present Review, we focus on therapeutic approaches that aim to block activated signaling pathways due to LOF of the BMP9-10/ALK1 signaling pathway, but another possibility would be to increase the deficient signaling pathway (more ligands, more receptors, activation of the downstream signaling pathway).

• #132

  https://www.jci.org/articles/view/176379

  A few years later, the first clinical trial using bevacizumab showed very positive results on 25 patients suffering from HHT. […] Today, with our current knowledge of the pathophysiological mechanisms of HHT owing to preclinical models and clinical trials, the main therapeutic lines of action to be considered include the following: first, avoiding angiogenic and inflammatory stimuli by all means, in line with the second hit hypothesis. […] Another important point is moving toward personalized medicine for each patient. […] It is therefore essential to monitor clinical improvement as a function of bevacizumab levels during maintenance therapy in order to maintain bioactive levels within the therapeutic window, especially if efficacy appears to be declining. […] Another aspect that should be considered more carefully is tailoring treatment to disease severity in order to limit drug toxicity.

• #133 Future treatments for hereditary hemorrhagic telangiectasia | Orphanet Journal of Rare Diseases | Full Text

  https://ojrd.biomedcentral.com/articles/10.1186/s13023-019-1281-4

  Hereditary Hemorrhagic Telangiectasia (HHT), also known as Rendu-Osler syndrome, is a genetic vascular disorder affecting 1 in 5000-8000 individuals worldwide. Presently, the therapeutic treatments for HHT are intended to reduce the symptoms of the disease. However, recent progress has been made using drugs that target VEGF (vascular endothelial growth factor) and the angiogenic pathway with the use of bevacizumab (anti-VEGF antibody). […] Although current treatments succeed pretty well at reducing recurrent epistaxis, there is still a need for magic bullets allowing to revert telangiectasias and AVMs into a normal vasculature and to definitely cure the disease. […] The first randomized phase III clinical trial to study bevacizumab efficiency and safety is now ongoing (NCT 03227263). […] Tacrolimus has been tested in several mouse models for HHT. It was found to decrease the number of retinal arteriovenous malformations induced by BMP9/10-immunodepletion in mice (HHT model).

• #134

  https://www.jci.org/articles/view/176379

  Hereditary hemorrhagic telangiectasia (HHT) is an inherited vascular disorder with highly variable expressivity, affecting up to 1 in 5,000 individuals. […] This Review presents up-to-date insights on this mutated signaling pathway and its crosstalk with proangiogenic pathways, in particular the VEGF pathway, that has allowed the repurposing of new drugs for HHT treatment. […] However, despite the substantial benefits of these new treatments in terms of alleviating symptom severity, this not-so-uncommon bleeding disorder still currently lacks any FDA- or European Medicines Agency-approved (EMA-approved) therapies. […] Awareness of the beneficial effect of blocking VEGF signaling in HHT patients dates back to 2006, when an HHT patient suffering from a malignant mesothelioma unexpectedly showed amelioration of HHT symptoms following antiangiogenic cancer treatment with an anti-VEGF-A monoclonal antibody (bevacizumab).

• #135 Osler-Weber-Rendu Disease (Hereditary Hemorrhagic Telangiectasia) Treatment & Management: Approach Considerations, Treatment of Epistaxis, Treatment of Gastrointestinal Bleeding

  https://emedicine.medscape.com/article/2048472-treatment

  In most patients, no special diet is required. Iron can be depleted if the patient experiences chronic blood loss. Folate requirements can be high if the bone marrow is chronically activated. Most patients can continue normal activities. […] Prospective trials aimed at determining ideal management of HHT have been limited by the small and varied population and by the multiorgan nature of the disease. A coordinated team approach is recommended. […] Preclinical work targeting endoglin (also known as CD105) has shown promising results in cancer-related research. […] Such studies may complement concurrent HHT-specific research in developing new therapies. […] In September 2020, the Second International Hereditary Hemorrhagic Telangiectasia (HHT) Guidelines, aimed at developing evidence-based consensus guidelines for the management and prevention of HHT-related symptoms and complications, were published.

• #136 Hereditary Hemorrhagic Telangiectasia (HHT) Treatment | University of Michigan Health

  https://www.uofmhealth.org/conditions-treatments/ear-nose-throat/hereditary-hemorrhagic-telangiectasia-hht-treatment

  Hereditary Hemorrhagic Telangiectasia (HHT) is a genetic disorder causing abnormal blood vessel development. […] There are many different specialists that are called upon to treat patients with HHT. […] To view Michigan Medicine providers who treat HHT, click on the physicians button in the upper right corner of the page, or click on the link to the same list of Michigan Medicine HHT providers. […] Treatment options can span from simple recommendations, such as humidification, to more sophisticated recommendations, such as laser treatment, surgical intervention, Avastin treatments, and sclerotherapy (injections to scar the small blood vessel abnormalities). […] Michigan Medicine otolaryngology specialists recognize that there are other types of blood vessel abnormalities, in different areas of the body, that may need to be found and treated to prevent complications from the disease and keep patients healthy.

• #137 Hereditary Hemorrhagic Telangiectasia (HHT) Treatment | University of Michigan Health

  https://www.uofmhealth.org/conditions-treatments/ear-nose-throat/hereditary-hemorrhagic-telangiectasia-hht-treatment

  Interventional radiologists treat patients with arteriovenous malformations (AVMs) of the lungs (occasionally elsewhere) with embolization (a procedure to plug circulation into the malformation). […] Hematologists help manage iron deficiency anemia and prescribe medications to enhance clotting. […] Pulmonary specialists help manage severe cases of HHT in the lungs, which occasionally causes shortness of breath, or interacts with other lung diseases. […] Gastroenterologists in our Small Bowel Bleeding program have particular expertise in treating vascular malformations in the gastrointestinal tract that bleed. […] Neurosurgeons occasionally perform surgery on patients with vascular malformations of the brain, to reduce the chance those malformations will bleed. […] Obstetricians evaluate women of child-bearing age or who may be pregnant, to address pregnancy-related issues.

• #138 Hereditary Hemorrhagic Telangiectasia (HHT) Treatment | University of Michigan Health

  https://www.uofmhealth.org/conditions-treatments/ear-nose-throat/hereditary-hemorrhagic-telangiectasia-hht-treatment

  Interventional radiologists treat patients with arteriovenous malformations (AVMs) of the lungs (occasionally elsewhere) with embolization (a procedure to plug circulation into the malformation). […] Hematologists help manage iron deficiency anemia and prescribe medications to enhance clotting. […] Pulmonary specialists help manage severe cases of HHT in the lungs, which occasionally causes shortness of breath, or interacts with other lung diseases. […] Gastroenterologists in our Small Bowel Bleeding program have particular expertise in treating vascular malformations in the gastrointestinal tract that bleed. […] Neurosurgeons occasionally perform surgery on patients with vascular malformations of the brain, to reduce the chance those malformations will bleed. […] Obstetricians evaluate women of child-bearing age or who may be pregnant, to address pregnancy-related issues.

• #139 Hereditary Hemorrhagic Telangiectasia (HHT) Treatment | University of Michigan Health

  https://www.uofmhealth.org/conditions-treatments/ear-nose-throat/hereditary-hemorrhagic-telangiectasia-hht-treatment

  Interventional radiologists treat patients with arteriovenous malformations (AVMs) of the lungs (occasionally elsewhere) with embolization (a procedure to plug circulation into the malformation). […] Hematologists help manage iron deficiency anemia and prescribe medications to enhance clotting. […] Pulmonary specialists help manage severe cases of HHT in the lungs, which occasionally causes shortness of breath, or interacts with other lung diseases. […] Gastroenterologists in our Small Bowel Bleeding program have particular expertise in treating vascular malformations in the gastrointestinal tract that bleed. […] Neurosurgeons occasionally perform surgery on patients with vascular malformations of the brain, to reduce the chance those malformations will bleed. […] Obstetricians evaluate women of child-bearing age or who may be pregnant, to address pregnancy-related issues.

• #140 Hereditary Hemorrhagic Telangiectasia (HHT) Treatment | University of Michigan Health

  https://www.uofmhealth.org/conditions-treatments/ear-nose-throat/hereditary-hemorrhagic-telangiectasia-hht-treatment

  Interventional radiologists treat patients with arteriovenous malformations (AVMs) of the lungs (occasionally elsewhere) with embolization (a procedure to plug circulation into the malformation). […] Hematologists help manage iron deficiency anemia and prescribe medications to enhance clotting. […] Pulmonary specialists help manage severe cases of HHT in the lungs, which occasionally causes shortness of breath, or interacts with other lung diseases. […] Gastroenterologists in our Small Bowel Bleeding program have particular expertise in treating vascular malformations in the gastrointestinal tract that bleed. […] Neurosurgeons occasionally perform surgery on patients with vascular malformations of the brain, to reduce the chance those malformations will bleed. […] Obstetricians evaluate women of child-bearing age or who may be pregnant, to address pregnancy-related issues.

• #141 Hereditary Hemorrhagic Telangiectasia (HHT) Treatment | University of Michigan Health

  https://www.uofmhealth.org/conditions-treatments/ear-nose-throat/hereditary-hemorrhagic-telangiectasia-hht-treatment

  Interventional radiologists treat patients with arteriovenous malformations (AVMs) of the lungs (occasionally elsewhere) with embolization (a procedure to plug circulation into the malformation). […] Hematologists help manage iron deficiency anemia and prescribe medications to enhance clotting. […] Pulmonary specialists help manage severe cases of HHT in the lungs, which occasionally causes shortness of breath, or interacts with other lung diseases. […] Gastroenterologists in our Small Bowel Bleeding program have particular expertise in treating vascular malformations in the gastrointestinal tract that bleed. […] Neurosurgeons occasionally perform surgery on patients with vascular malformations of the brain, to reduce the chance those malformations will bleed. […] Obstetricians evaluate women of child-bearing age or who may be pregnant, to address pregnancy-related issues.

• #142 Hereditary Hemorrhagic Telangiectasia (HHT) Treatment | University of Michigan Health

  https://www.uofmhealth.org/conditions-treatments/ear-nose-throat/hereditary-hemorrhagic-telangiectasia-hht-treatment

  Interventional radiologists treat patients with arteriovenous malformations (AVMs) of the lungs (occasionally elsewhere) with embolization (a procedure to plug circulation into the malformation). […] Hematologists help manage iron deficiency anemia and prescribe medications to enhance clotting. […] Pulmonary specialists help manage severe cases of HHT in the lungs, which occasionally causes shortness of breath, or interacts with other lung diseases. […] Gastroenterologists in our Small Bowel Bleeding program have particular expertise in treating vascular malformations in the gastrointestinal tract that bleed. […] Neurosurgeons occasionally perform surgery on patients with vascular malformations of the brain, to reduce the chance those malformations will bleed. […] Obstetricians evaluate women of child-bearing age or who may be pregnant, to address pregnancy-related issues.

• #143 Hereditary Hemorrhagic Telangiectasia (HHT) Treatment | University of Michigan Health

  https://www.uofmhealth.org/conditions-treatments/ear-nose-throat/hereditary-hemorrhagic-telangiectasia-hht-treatment

  Interventional radiologists treat patients with arteriovenous malformations (AVMs) of the lungs (occasionally elsewhere) with embolization (a procedure to plug circulation into the malformation). […] Hematologists help manage iron deficiency anemia and prescribe medications to enhance clotting. […] Pulmonary specialists help manage severe cases of HHT in the lungs, which occasionally causes shortness of breath, or interacts with other lung diseases. […] Gastroenterologists in our Small Bowel Bleeding program have particular expertise in treating vascular malformations in the gastrointestinal tract that bleed. […] Neurosurgeons occasionally perform surgery on patients with vascular malformations of the brain, to reduce the chance those malformations will bleed. […] Obstetricians evaluate women of child-bearing age or who may be pregnant, to address pregnancy-related issues.

• #144 Hereditary Hemorrhagic Telangiectasia (HHT) Treatment | University of Michigan Health

  https://www.uofmhealth.org/conditions-treatments/ear-nose-throat/hereditary-hemorrhagic-telangiectasia-hht-treatment

  Cardiologists and heart failure specialists may see a subset of HHT patients, usually older patients, who may have developed some congestive heart failure related to HHT, vascular malformations, or liver involvement by HHT. […] Our cosmetic dermatologists are called upon to treat skin telangiectasias and other vascular skin lesions, often with laser treatments, for cosmetic reasons or to reduce bleeding from skin lesions. […] Radiation oncologists may be asked to assess and treat patients brain vascular malformations with radiation therapy or gamma knife, for instance, instead of surgery. […] We encourage patients to have their HHT mutation identified by genetic testing, because it may affect treatment recommendations and also makes it easier to test other family members or newborn relatives. […] Liver specialists are occasionally called upon for patients with uncommon yet significant liver involvement with large AVMs. […] Very rarely patients have severe liver AVMs.

• #145 Hereditary Hemorrhagic Telangiectasia (HHT) Treatment | University of Michigan Health

  https://www.uofmhealth.org/conditions-treatments/ear-nose-throat/hereditary-hemorrhagic-telangiectasia-hht-treatment

  Cardiologists and heart failure specialists may see a subset of HHT patients, usually older patients, who may have developed some congestive heart failure related to HHT, vascular malformations, or liver involvement by HHT. […] Our cosmetic dermatologists are called upon to treat skin telangiectasias and other vascular skin lesions, often with laser treatments, for cosmetic reasons or to reduce bleeding from skin lesions. […] Radiation oncologists may be asked to assess and treat patients brain vascular malformations with radiation therapy or gamma knife, for instance, instead of surgery. […] We encourage patients to have their HHT mutation identified by genetic testing, because it may affect treatment recommendations and also makes it easier to test other family members or newborn relatives. […] Liver specialists are occasionally called upon for patients with uncommon yet significant liver involvement with large AVMs. […] Very rarely patients have severe liver AVMs.

• #146 Hereditary Hemorrhagic Telangiectasia (Osler-Weber-Rendu Syndrome) | Cedars-Sinai

  https://www.cedars-sinai.org/health-library/diseases-and-conditions/h/hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome.html

  There is no cure for hereditary hemorrhagic telangiectasia. Treatment for the condition generally is focused on managing the symptoms. […] Nosebleeds are managed through the use of humidifiers, nasal lubrication or applying pressure to the affected area. Severe cases may require surgery to stop the bleeding. […] If the gastrointestinal tract is affected by the condition, iron replacement therapy is used as treatment. Other medicines may be prescribed for the condition, and endoscopic ablation (removal of diseased tissue) may also be used. Some patients with severe cases of anemia may need a blood transfusion. When the condition affects blood vessels in the brain, treatment may include surgery, intentional blockage of an artery (embolotherapy) and stereotactic radiosurgery. […] For patients who have experienced a stroke, the Stroke Program at Cedars-Sinai provides a multidisciplinary treatment approach through a treatment plan tailored to each patient. Patient care is generally broken down into three categories: stroke prevention, treatment immediately after a stroke and post-stroke rehabilitation. […] For patients with a hereditary condition, genetic counseling, available through the Cedars-Sinai Medical Genetics Institute, can help identify families at risk and provide referrals to specialized health care providers.

• #147 Raising Awareness for Hereditary Hemorrhagic Telangiectasia (HHT) at UCSF | UCSF Radiology

  https://radiology.ucsf.edu/blog/raising-awareness-hereditary-hemorrhagic-telangiectasia-hht-ucsf

  HHT is a genetic disorder characterized by abnormal blood vessel growth. These lesions typically appear in the brain, lungs, liver, and gastrointestinal tract, and can cause sudden stroke, heart failure, and pulmonary hypertension if untreated. […] The complexities of HHT require a comprehensive and versatile approach to care. […] The HHT clinic also conducts regular follow-up with patients, conducting imaging studies every one to five years to monitor the progression of lesions. […] This holistic approach aims to provide continuous and tailored care to each patient and contributes to HHT Centers of Excellence demonstrating positive patient outcomes such as fewer hospitalizations, less loss of life, and higher quality of life. […] UCSFs HHT Center of Excellence stands out, with a multidisciplinary team of diagnostic interventional and neurointerventional radiologists, cardiologists, hepatologists, dermatologists, hematologists, neurologists, otolaryngologists, pulmonologists, and neurosurgeons dedicated to addressing the diverse challenges posed by HHT.

• #148 Hereditary Hemorrhagic Telangiectasia (HHT) and Survival: The Importance of Systematic Screening and Treatment in HHT Centers of Excellence

  https://www.mdpi.com/2077-0383/9/11/3581

  Our study shows that the life expectancy of patients, who are screened for HHT-related organ involvement and if needed, treated in a center with HHT expertise, is similar to the life expectancy of their relatives without HHT. […] These findings demonstrate the importance of systematic screening of HHT patients and treatment of PAVMs and other HHT-related organ involvement.

Zobacz więcej